Skip to main content
PLOS Pathogens logoLink to PLOS Pathogens
. 2021 Dec 6;17(12):e1010113. doi: 10.1371/journal.ppat.1010113

Genome-scale CRISPR screen identifies TMEM41B as a multi-function host factor required for coronavirus replication

Limeng Sun 1,2,#, Changzhi Zhao 3,#, Zhen Fu 1,2, Yanan Fu 1,2, Zhelin Su 1,2, Yangyang Li 4, Yuan Zhou 3, Yubei Tan 1,2, Jingjin Li 3, Yixin Xiang 1,2, Xiongwei Nie 3, Jinfu Zhang 3, Fei Liu 4, Shuhong Zhao 3,5, Shengsong Xie 3,*, Guiqing Peng 1,2,*
Editor: Sabra L Klein6
PMCID: PMC8675922  PMID: 34871328

Abstract

Emerging coronaviruses (CoVs) pose a severe threat to human and animal health worldwide. To identify host factors required for CoV infection, we used α-CoV transmissible gastroenteritis virus (TGEV) as a model for genome-scale CRISPR knockout (KO) screening. Transmembrane protein 41B (TMEM41B) was found to be a bona fide host factor involved in infection by CoV and three additional virus families. We found that TMEM41B is critical for the internalization and early-stage replication of TGEV. Notably, our results also showed that cells lacking TMEM41B are unable to form the double-membrane vesicles necessary for TGEV replication, indicating that TMEM41B contributes to the formation of CoV replication organelles. Lastly, our data from a mouse infection model showed that the KO of this factor can strongly inhibit viral infection and delay the progression of a CoV disease. Our study revealed that targeting TMEM41B is a highly promising approach for the development of broad-spectrum anti-viral therapeutics.

Author summary

Coronaviruses (CoVs) pose a severe threat to human and animal health. Identification of host genes essential for transmissible gastroenteritis virus (TGEV) infection may reveal novel therapeutic targets and strengthen our understanding of CoV disease pathogenesis. We performed genome-wide and sub-pooled CRISPR screens in porcine kidney cells with TGEV. We identified numerous candidate host factors for TGEV infection. Considering its extremely strong effect on TGEV infection, we focused our efforts on characterizing the roles that TMEM41B play in the virus replication cycle. Our results revealed that TMEM41B contributed to CoV internalization and the formation of replication organelles. TMEM41B is critical for the replication of TGEV and other RNA viruses. Our mouse infection model provides strong evidence that knocking out the TMEM41B gene can inhibit viral infection and delay the progression of a CoV disease. Our study identified potential therapeutic targets for common RNA viruses and reveals host factors that regulate susceptibility to highly pathogenic CoVs.

Introduction

As enveloped positive-strand RNA viruses, coronaviruses (CoVs) have genetically evolved into the following four major genera: α, β, γ, and δ. CoVs cause various diseases in mammals and birds, ranging from enteritis in pigs to potentially lethal human respiratory infections [1,2]. For instance, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which belongs to the β-CoV genera, is a causative viral pathogen that causes upper respiratory diseases, fever, and severe pneumonia in humans [3] and currently presents a global public health threat. Transmissible gastroenteritis virus (TGEV), together with several human CoVs (e.g., HCoV-NL63 and HCoV-229E), belongs to the α-CoV genera. TGEV causes severe diarrhea, vomiting, and dehydration, with mortality rates of 100% in piglets less than 2 weeks old, which causes significant economic losses in the pork industry worldwide [4,5]. Mouse hepatitis virus (MHV), belonging to the β-CoV genera, is a natural pathogen that specifically infects mice. MHV can cause numerous diseases through different inoculation routes, such as the liver, gastrointestinal tract, and central nervous system [6,7]. The MHV-A59 strain can produce moderate to severe hepatitis, mild to moderate acute meningoencephalitis, and chronic demyelination in C57BL/6 weanling mice [8]. MHV infection of mice is considered one of the suitable animal models for the study of CoV-host interactions [912].

Although numerous CoVs exist, they employ a relatively conservative replication strategy. The positive single-stranded RNA genome needs to be released into the cytosol to initiate infection. To do so, CoVs bind to host-encoded receptors [1316] through their spike (S) glycoproteins, and the S2 domain adopts a post-fusion conformation after being cleaved by the host’s various proteases for membrane fusion [1720]. Subsequently, the viral RNA is released into the cytoplasm where the viral RNA is translated to generate the viral replication/transcription complex [21,22], and virions are then assembled and bud. Various host protein-coding genes are involved as critical factors in the CoV replication process [23]. Therefore, the identification of essential genes for the interaction between the virus and host cells can facilitate the development of targeted drugs for treating diseases related to CoV infections [2426].

CRISPR screening has proven to be a powerful tool for identifying host factors necessary for infection by different viruses, such as SARS-CoV-2 [27,28], influenza A virus (IAV) [29], and Japanese encephalitis virus (JEV) [30]. In the present study, genome-wide CRISPR-based knockout (KO) screening was performed to specifically identify host factors required for TGEV replication in porcine kidney-15 (PK-15) cells. Among other identified host factors, we focused on TMEM41B and showed that this protein is required for the infection by CoV and other viruses. Our results revealed that the KO of TMEM41B inhibits the internalization and early-stage replication of CoV. Notably, we found that TMEM41B contributes to the formation of CoV replication organelles (ROs). Our study emphasized the significance of TMEM41B for CoV infection in vivo and in vitro which indicates that TMEM41B may be a vulnerable target for the development of anti-CoV therapeutics.

Results

A genome-scale CRISPR screen identified host factors associated with CoV TGEV infection

To identify host factors involved in α-CoV TGEV replication, we generated a porcine genome-scale CRISPR/Cas9 knockout (PigGeCKO) cell collection (in the PK-15 background) as described in a previous study [30] and performed a genome-wide loss-of-function genetic screen. Prior to screening, we first examined TGEV-induced cell death following infection at multiplicity of infection (MOI) values of 0, 0.001, 0.01, and 0.1. We observed cytopathic effects for the different MOIs at approximately 3 days after TGEV infection (S1 Fig). Here, we chose the optimal titer for TGEV-induced cell death in PK-15 cells with an MOI of 0.001. Subsequently, we performed screening to identify host factors that modulate susceptibility to TGEV-induced cell death. The overall PigGeCKO screening strategy is illustrated in Fig 1A. We first conducted three rounds of TGEV challenge, employing untreated Cas9 stably expressed (PK-15-Cas9) cells as a negative control to confirm cell death caused by TGEV infection in each round. At an MOI of 0.001, all untreated TGEV-infected PK-15-Cas9 cells died, whereas a small number of viable cells from the TGEV-infected PigGeCKO cell collection were observed. The surviving mutant cells were collected and used for subsequent TGEV challenge rounds. Lastly, small guide RNA (sgRNA) constructs in surviving mutant cells from the three rounds were polymerase chain reaction (PCR) amplified and deep sequenced.

Fig 1. Genome-wide CRISPR screening to identify genes associated with alpha-CoVs TGEV-induced cell death.

Fig 1

(A) Identification of TGEV host factors using the porcine genome-scale CRISPR/Cas9 knockout (PigGeCKO) library. Transformed PK-15-Cas9 cells were either mock-treated or challenged with TGEV (MOI = 0.001). Surviving cells from each round of virus challenge were isolated, with the subsequent PCR amplification and sequencing of sgRNA. (B-D) Scatter plots showing sgRNA-targeted sequence frequencies and the extent of enrichment in transformed PK-15-Cas9 cells (mock-treated versus TGEV infected) in three rounds of TGEV screening; (B) first, (C) second and (D) third, respectively. Counts_TGEV1st/Counts_TGEV2nd and Counts_TGEV3rd are the average reads from the paired-end sequencing for each round. Log2(fold change) is the median log 2 ratio between normalized sgRNA count of TGEV challenged and mock-treated populations. (E and F) Venn diagrams indicate the scope of overlapping enrichment in specific sgRNA targeting sequences for the three TGEV screening rounds amongst the top (E) ~0.1% and (F) ~0.5% of averaged sgRNAs reads. FACS, Fluorescence Activated Cell Sorting; TGEV, Transmissible gastroenteritis virus; sgRNA, small guide RNA.

Our screening revealed that a total of 335 unique sgRNA sequences, which targeted 317 unique protein-coding genes, were present in at least ~0.1% of the total number of cells analyzed from each round of TGEV challenge (S1 Data). As expected, aminopeptidase N (ANPEP), the already known functional receptor of TGEV [31,32], was significantly enriched in all three rounds of CRISPR screening (Fig 1B–1D). Among the top 0.1% of sgRNAs, multiple sgRNAs targeting the same gene were identified. For example, in the second challenge rounds, two and three sgRNAs hit the ANPEP and TMEM41B genes, respectively (S1 Data). Note that in general, a high number of sgRNA reads typically indicates the KO of the targeted gene, which confers strong resistance to TGEV-induced cell death but does not affect cell growth. A comparison of enriched sgRNAs from the positive selection CRISPR screening revealed that 76.7% of the very highly enriched (i.e., ≧ 0.1%) sequences were common to the first, second, and third challenge rounds, and that 82.8% of the highly enriched (≧ 0.5%) sequences were common to all three rounds (Fig 1E and 1F). These results suggested that the candidate host factors related to TGEV infection are reliable based on our CRISPR screening strategy.

TMEM41B is a host factor required for CoV TGEV replication

We also performed a focused-CRISPR library screening which examined the 79 top-ranked candidate host factors from the PigGeCKO screen; note that we excluded any sgRNA targeting the previously identified ANPEP receptor (S2 Data). In addition, a high virus titer (MOI = 1) was used to identify KO cells with a strong ability to inhibit TGEV infection. The 10 top-ranking candidates after the third and fifth challenge rounds were FUT8, TMEM41B, DYRK1A, MLST8, etc. from highest to lowest (Fig 2A). In addition, four sgRNAs were found to hit TMEM41B in the third and fifth challenge rounds, indicating that hitting the target should be reliable (Fig 2A). Afterward, five candidates (i.e., ANPEP, TMEM41B, LPP, TAX1BP, and BARHL2) were selected for further analysis. Sanger sequencing confirmed that each of these single-clone-originated KO cell lines had one or more nucleotide deletions predicted to cause a frameshift mutation in the coding regions of the targeted gene (a non-integer multiple of 3) (S2 Fig). We found that the individual KO of these genes reduced viral loads in PK-15 cells (Fig 2B). This finding coincides with the immunofluorescence assays showing that the expression of the TGEV-encoded nucleocapsid (N) protein in five KO cell lines was reduced or undetectable following TGEV infection at an MOI of 0.1 (Fig 2C).

Fig 2. TMEM41B is a host factor required for TGEV replication.

Fig 2

(A) Verification of candidate genes enriched in the genome-wide CRISPR screen using a second, focused-CRISPR library screen. Scatter plots compare sgRNA targeted sequence frequencies and the extent of enrichment in the transformed PK-15-Cas9 cells (mock-treated versus TGEV infected) for the third (TGEV3rd) and fifth (TGEV5th) rounds of TGEV screening. Counts_TGEV3rd and Counts_TGEV5th represent the average values of the read counts from paired-end sequencing. Log2(fold change) is the median log 2 ratio between normalized sgRNA count of TGEV challenged and mock-treated cell populations. (B) Quantification of virus infectivity (TCID50) in culture supernatant collected 24 hpi from TGEV-infected (MOI = 0.1) WT and KO (ANPEP, TMEM41B, LPP, TAX1BP1, BARHL12) cell lines. (C) Immunofluorescence assays for detection of the TGEV N protein in WT cells and five selected genes (ANPEP, TMEM41B, LPP, TAX1BP1, BARHL12) KO cells following infection with TGEV (MOI = 0.1) at 24 hpi. Scale bar, 200 μm. (D) Western blot assay to detect the TGEV N protein expressed in TMEM41B KO and WT cells following infection with TGEV (MOI = 1) at 24 hpi. GAPDH used as an internal control gene. (E) Viral quantification by plaque assays. TMEM41B KO and WT cells were seeded into 24-well culture plates and infected with TGEV at different MOIs (0, 0.001, 0.01, 0.1, 1 and 10). Plates stained with 1% crystal violet to view plaques. (F) TMEM41B KO and WT cells were infected with TGEV at different MOIs (0.001 and 1), TGEV N copy number was assessed by absolute quantitative real-time PCR. (G and H) Rescue assays for WT, TMEM41B-KO and TMEM41B-KO-rescue cells infected with TGEV (MOI = 1). RT-qPCR assay for determination of (G) relative mRNA level of TMEM41B and (H) absolute mRNA level of TGEV N gene. TMEM41B-KO-rescue: reconstituted TMEM41B in TMEM41B KO cells. (I and J) Overexpression of TMEM41B in PK-15 control cells following infection with TGEV (MOI = 1). RT-qPCR assay for the determination of (I) relative mRNA level of TMEM41B and (J) absolute mRNA level of the TGEV N gene. PK-15-NTC: Transfection of pcDNA3.1 empty vector in WT cells; PK-15-overexpression: Transfection of pcDNA3.1-TMEM41B vector in WT cells. WT, wild-type; KO, knockout; MOI, multiplicity of infection; kDa, kilodaltons; DAPI, 4’,6-diamidino-2-phenylindole. **P < 0.01; ***P < 0.001; ****P <0.0001. P values were determined by two-tailed Student’s t-tests. Data are represented as a percentage mean titer of triplicate samples relative to WT control cells ± S.D.

We prioritized TMEM41B for further mechanistic studies on TGEV replication, because the KO of this gene conferred a relatively strong ability to inhibit TGEV (MOI = 1) replication. The ability of TMEM41B KO cells to inhibit TGEV replication was near the level that we observed for ANPEP KO cells (Fig 2B and 2C). Western blot showed that the KO of TMEM41B can block the accumulation of the TGEV N protein (Fig 2D). Subsequently, plaque assays revealed that TMEM41B KO cells can remain viable after TGEV infection with MOIs of 0.001, 0.01, 0.1, 1, and 10 (Fig 2E). Moreover, as shown in Fig 2F, knocking out TMEM41B significantly reduced TGEV RNA replication at MOIs of 0.001 and 1. To detect whether TMEM41B is required for TGEV infection, we constructed a CRISPR-resistant TMEM41B-KO-rescue cell line, which stably expressed the TMEM41B gene on its KO cells (S2 Fig). As shown in Fig 2G and 2H, the TGEV replication on TMEM41B-KO-rescue cells can be restored completely as compared with the wild-type (WT) cells. Furthermore, overexpression of TMEM41B in WT cells can promote TGEV replication (Fig 2I and 2J). These results indicated that TMEM41B as a critical gene participates in TGEV replication. In addition, no differences were detected in the rates of DNA synthesis or cell proliferation between TMEM41B KO and WT cells in EdU fluorescence assays or cell proliferation assays (MTS), respectively (S3B and S3C Fig).

Subsequently, the role in TGEV replication of other TMEM41B homologous proteins with a VTT domain (collectively referred to as DedA domains), such as Transmembrane Protein 41A (TMEM41A) and vacuole membrane protein 1 (VMP1), was determined [33]. Compared with TMEM41B KO cells, we found that knocking out TMEM41A did not inhibit TGEV infection, while VMP1 KO cells were partially resistant to TGEV infection (S4A and S4B Fig). These results indicated that the VTT-domain protein TMEM41B was more important than the other two genes in TGEV infection. To further determine whether knocking out TMEM41B can inhibit TGEV infection in other porcine cells, we also performed experiments with swine testicle (ST) cells, which were previously demonstrated to be susceptible to TGEV infection; results revealed that TMEM41B KO ST cells were not readily infected by TGEV (S4C Fig). Thus, our CRISPR-based screening strategy discovered numerous candidate host factors related to the replication of the α-CoV TGEV, and we demonstrated that TMEM41B is an essential host factor for TGEV replication.

TMEM41B is an intrinsic negative regulator of innate immune responses, but this protein does not participate in TGEV replication through the interferon signaling pathway

TMEM41B is predicted to contain six transmembrane domains and to localize to the endoplasmic reticulum (ER). Considering the known function of TMEM41B in the canonical autophagy pathway [3436], we attempted to determine whether the canonical autophagy pathway is essential for TGEV infection. We generated an autophagy related gene 5 (ATG5) KO cell line, which is an essential molecule for autophagy induction [37]. Our Western blot results showed that ATG5 KO cells produced significantly less lipidated microtubule-associated protein 1A/1B-light chain 3 (LC3)-II upon starvation and aloxistatin (E64d) conditions compared with WT cells, confirming the inability of ATG5 KO cells to initiate autophagy (S5 Fig, middle). However, the ATG5 KO and WT cells remained susceptible to TGEV infection (S5 Fig, right). These findings suggested that the canonical autophagy pathway is not required for TGEV replication.

We subsequently explored the potential downstream signaling pathways affected by the KO of TMEM41B and their potential relationships to the observed inhibition of TGEV replication. RNA sequencing (RNA-seq) was performed with the total RNA isolated from uninfected and TGEV-infected TMEM41B KO and WT cells (Sheets A-D in S3 Data). Unexpectedly, a comparison of the transcriptomes of TGEV-uninfected WT and TMEM41B KO cells, with more than 1,115 differentially expressed genes (DEGs), indicated that TMEM41B KO cells exhibited altered expression of multiple genes related to several aspects of biological functions (Sheet C in S3 Data). Protein–protein interaction (PPI) network analysis revealed that upregulated genes in TMEM41B KO cells were enriched in “interferon signaling” (S6S9 Figs). Meanwhile, highly expressed interferon-stimulated genes (ISGs) in TMEM41B KO cells were most significantly associated with interferon signaling pathways according to Gene Set Enrichment Analysis (GSEA) (Fig 3A–3D). The differentially expressed ISGs, such as MX1, OASL, IFIT1, IFI6, and RSAD2, were then selected to undergo verification via quantitative reverse transcription PCR (RT-qPCR). The relative expression levels of the genes from RT-qPCR were consistent with those from the RNA-seq data (Fig 3E and Sheets A-D in S3 Data).

Fig 3. TMEM41B is an intrinsic negative regulator of innate immune responses.

Fig 3

(A-D) Gene Set Enrichment Analysis (GSEA) for differentially expressed genes from the RNA-seq data shows a distinct upregulation of the interferon signaling pathway across the four pairwise groups (A) WT-MOCK vs WT-TGEV; (B) TMEM41B-KO-MOCK vs TMEM41B-KO-TGEV; (C) WT-MOCK vs TMEM41B-KO-MOCK; (D) WT-TGEV vs TMEM41B-KO-TGEV. (E) RT-qPCR validation of the mRNA expression of ISGs selected by RNA-seq results. (F) RT-qPCR outcome reveal that the stable rescue of TMEM41B in TMEM41B KO cells led to the significant suppression of genes associated with the interferon signaling pathway. (G) Viral titers for WT, TMEM41B-KO and TMEM41B/IFNAR double KO cells infected with TGEV. The TMEM41B/IFNAR double KO cells still maintain the ability to resist TGEV replication compared with TMEM41B KO cells as determined by the TCID50 assay. WT, wild-type; KO, knockout; hpi, hours post-infection; MOCK, uninfected cells; TGEV, Transmissible gastroenteritis virus infected cells. *P < 0.05; **P < 0.01; ***P < 0.001. P values were determined by two-sided Student’s t-test. Data are representative of at least three independent experiments.

To determine whether the ISG-activation signature was specific to the loss of TMEM41B function, we performed rescue experiments and found that the mRNA expression of MX1, OASL, IFIT1, IFI6, and RSAD2 in TMEM41B-KO-rescue cells decreased to WT level (Fig 3F). In addition, TMEM41B KO human HEK293T cells and mouse L929 cells were generated by CRISPR/Cas9 technology (S10A and S10C Fig). Compared with TMEM41B KO PK-15 cells, knocking out TMEM41B only slightly increased ISG expression levels in HEK293T and L929 cells, indicating that the ability to upregulate ISGs varies by cell type (S10B and S10D Fig). We further detected the mRNA expression of ISGs in WT cells by stably expressing TMEM41B after stimulation with polyinosinic acid–polycytidylic acid (PolyI:C), a synthetic double-stranded RNA (dsRNA) analog which is an immunostimulant that acts as the most potent interferon inducer [38]. Compared with WT cells, TMEM41B overexpression can significantly reduce ISG expression levels, thereby inhibiting the host response to PolyI:C stimulation (S11A–S11E Fig). Subsequently, we investigated whether the interferon signaling pathway is involved in the TGEV replication in TMEM41B KO cells. TMEM41B and IFNAR (interferon-α/β receptor) double PK-15 KO cells were generated. Compared with TMEM41B KO cells, the expression levels of several ISGs (i.e., RASD2, OASL, and IFIT1) in TMEM41B and IFNAR double KO cells were reduced, almost to the same level as those of WT cells (S11F–S11H Fig). However, double KO cells retained a strong ability to inhibit TGEV replication (Fig 3G). Overall, these results revealed that TMEM41B plays an intrinsic negative regulation role in immunity response, which does not inhibit TGEV replication by IFNAR-mediated activation of the interferon signaling pathway.

TMEM41B KO inhibits the internalization and early-stage replication of TGEV

We next investigated which stages of TGEV replication were affected in TMEM41B KO cells. The absorption rate of virus particles in TMEM41B KO and WT cells at 4°C for 1 h was measured. The result showed that these two cell lines had the same absorption capacity of virus particles (Fig 4A). We found that the positive fluorescence signal of TGEV N protein is evenly distributed on the cell membrane of TMEM41B KO and WT cells, indicating that virus particles can still bind to TMEM41B KO cells (Fig 4B). These results suggested that knocking out TMEM41B does not affect the absorption of virus particles by PK-15 cells. Subsequently, we performed confocal microscopy to investigate viral endocytosis stage. TMEM41B KO or WT cells were first challenged with TGEV (MOI = 50) at 37°C for 30 min, and the expression levels of TGEV N protein were monitored as a reporter for the internalization of virions. The fluorescence signal of the N protein in the cytoplasm of TMEM41B KO cells was significantly reduced compared with those of WT cells (Fig 4C, left); the normalized mean fluorescence intensity data indicated that the extent of virion internalization decreased by approximately 30% in TMEM41B KO cells (Fig 4C, right). Our transcriptome data (Sheets A-D in S3 Data) and subsequent RT-qPCR validation data for TMEM41B KO and WT cells highlighted that some of the significantly downregulated genes (e.g., DAB2, THRB) have functions related to endocytosis (Fig 4D). Thus, TMEM41B possibly contributes to TGEV replication by affecting several endocytosis-related processes through which the virus is internalized into cells.

Fig 4. The internalization and early-stage replication of TGEV were impaired on TMEM41B KO cells.

Fig 4

(A) Evaluation of the adsorption activity of TGEV on TMEM41B KO and WT cells by absolute quantitative real-time PCR assay. WT and TMEM41B KO cells were infected with TGEV (MOI = 5) at 4°C for 1 h and assessed for TGEV adsorption. (B) Confocal microscopy assay for detection of TGEV N protein (Red) on WT and TMEM41B KO cells infected with TGEV (MOI = 5) at 4°C for 1 h. Scale bars = 5 μm. (C) Evaluation of the TGEV endocytosis stage in TMEM41B KO cells. WT and KO cells were infected with TGEV (MOI = 50) at 4°C for 1 h and transferred to 37°C for 30 min. Left: Confocal microscopy assay for detection of TGEV N protein (Red) expression in TMEM41B KO and WT cells. Right: Normalized mean fluorescence intensity was standardized by the ratio of each fluorescence intensity was divided by the maximum fluorescence intensity, n≧3. Scale bars = 10 μm. (D) RT-qPCR validation of mRNA expression of endocytic pathway genes enriched by RNA-seq. (E) Evaluation of the effects of TMEM41B KO cells on virus particle assembly by transmission electron microscope. Compared with WT cells, no virus-like particles (red arrows) wrapped in vesicles of varying sizes were found in TMEM41B KO cells. Scale bar, 2 μm or 500 nm as indicated. (F) Assessment of TGEV release stage of replication in TMEM41B KO and WT cells infected with TGEV (MOI = 5). Intracellular and extracellular viral titers were evaluated by virus TCID50 assays at 24 hpi. (G and H) Confocal microscopy to evaluate early-stage TGEV replication by detecting (G) dsRNA formation and (H) TGEV N protein expression in WT and TMEM41B KO cells infected with TGEV (MOI = 5) at 3 hpi. WT, wild-type; KO, knock out; hpi, hours post-infection; MOI, multiplicity of infection; Mock, uninfected cells; TGEV, Transmissible gastroenteritis virus infected cells; N, Nucleus, dsRNA, double-stranded RNA; DAPI, 4’,6-diamidino-2-phenylindole. **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, no significant. P values were determined by two-sided Student’s t-test. Data are representative of at least three independent experiments.

Furthermore, we performed transmission electron microscopy (TEM) to evaluate the effects of knocking out TMEM41B on virus particle assembly. Unlike WT cells, no vesicle-wrapped virus-like particles were produced in TMEM41B KO cells (Fig 4E). The extracellular and intracellular viral titers of TMEM41B KO cells were approximately equal and both lower than those of WT cells (Fig 4F). These results thus suggested that knocking out TMEM41B severely impaired virion production. We found that TMEM41B KO only partially suppressed TGEV internalization (Fig 4C), but this result does not fully explain the observed inhibition of TGEV replication. We therefore examined the early-stage replication of TGEV in TMEM41B KO and WT cells. Confocal microscopy analysis indicated that dsRNA formation (Fig 4G) and TGEV N protein accumulation (Fig 4H) were inhibited almost entirely in TMEM41B KO cells by 3 h post-infection (hpi) upon TGEV infection. Considering that dsRNA acts as the intermediate of CoV replication, these results revealed that TMEM41B is important not only for the internalization stage but also for the early-stage replication of TGEV infection.

TMEM41B contributes to the formation of CoV ROs

Similar to several other positive-strand RNA viruses of eukaryotes, CoV infection hijacks the intracellular membranes of host cells to form double-membrane vesicles (DMVs) [3942]. Previous studies revealed that DMVs are a prominent type of viral ROs [4346]. TMEM41B is an ER transmembrane protein previously reported to be required for phagophore maturation [35]. Considering that parts of the autophagy process show similarities to DMV formation [4749], we hypothesized that TMEM41B may participate in CoV DMV formation. Thus, we performed TEM assay to evaluate the ability of CoV RO formation in TMEM41B KO and WT cells. We detected typical DMVs (diameter ~200 nm) in WT cells upon TGEV infection (Fig 5A and 5B). Other types of ROs were also found in the TGEV-infected WT cells, including the small open double-membrane spherules (DMSs) and irregular coiled membrane formed by ER expansion (Fig 5C and 5D). The number of DMVs between TMEM41B KO and WT cells were calculated. In the 68 random observation fields of TGEV-infected WT cells by TEM assay, ~35 DMVs with a diameter of ~200 nm were found. By contrast, no obvious DMVs were observed in TMEM41B KO cells (Fig 5E and 5F). We found that numerous vesicles were present in TMEM41B KO cells (Fig 5E and 5F). In contrast with virus-induced organelles, the vesicles were monolayered and had different morphologies with varying sizes. These unidentified vesicles were similar to the previously reported features, which may be the precursor of the autophagosome that originated from the ER membrane [34].

Fig 5. TMEM41B contributes to the formation of CoVs replication organelles.

Fig 5

(A-D) Representative images from transmission electron microscope of TGEV (MOI = 0.1, 24 h) induces membrane structures. There are typical DMVs (diameter ~200 nm) were observed (A and B). Electron micrograph of an area with abundant double-membrane spherule (DMSs) (C) and irregular coiled membrane formed by ERs expansion (D). Scale bar, 1μm or 500 nm. (E-F) Electron micrograph showing mock-infected and TGEV-infected (MOI = 0.1, 24 h) TMEM41B KO cells bearing several monolayer vesicles. Scale bar, 500 nm or 250 nm. (G) Confocal fluorescence microscopy analysis of the co-localization of TGEV-NSP3-HA (indicated in red) and restored expression of TMEM41B-FLAG (indicated in fuchsia) in TMEM41B KO cells. Scale bar, 5 μm. (H) Analysis of the subcellular location of ectopic expression TMEM41B in KO cells mock-infected (above) or infected with TGEV (MOI = 1, 12 h) (bottom). The restored expression of TMEM41B (indicated in red) were co-localization with dsRNA (indicated in green). Scale bar, 5 μm. (I) Assessment of the co-localization of dsRNA (indicated in green) and ectopic expression of TMEM41B-FLAG (indicated in red) in L929 cells during MHV (MOI = 1, 12 h) infection via confocal fluorescence microscopy. Scale bar, 5 μm. (J) A model for the role of TMEM41B in the formation of coronavirus replication organelles. WT, wild-type; KO, knock out; Mock, uninfected cells; TGEV, Transmissible gastroenteritis virus infected cells; MHV, Mouse hepatitis virus infected cells; M, Mitochondria; ER, Endoplasmic reticulum; DAPI, 4’,6-diamidino-2-phenylindole; HA, HA-Tag; FALG, 3×FLAG-Tag; dsRNA, double-stranded RNA.

We subsequently co-transfected CoV nonstructural protein 3 (NSP3) and TMEM41B into TMEM41B KO cells. Confocal fluorescence results showed that TMEM41B and NSP3 are co-localized (Fig 5G). Previous studies have shown that the CoV NSP3 participates in CoV DMV formation [25,5052]. Our results thus suggested that TMEM41B may act together with the CoV NSP3 in DMV formation. Moreover, subcellular localization of TMEM41B heterologous expression was detected in uninfected or TGEV-infected TMEM41B KO cells. We found that TMEM41B that were expressed in the uninfected KO cells exhibited diffusion in the reticular structure and filling up of the cytoplasm (Fig 5H). By contrast, the fluorescent signal of TMEM41B was significantly accumulated in TGEV-infected KO cells, and the positive signal was co-localized with dsRNA (Fig 5H). We also found that murine TMEM41B co-localized with dsRNA when mouse fibroblasts (L929 cells) were infected with the MHV-A59 strain (Fig 5I). DsRNA was used as a marker for positive-stranded RNA virus replication that always exists in DMVs [46,53]; we thus speculated that the recruitment of TMEM41B to dsRNA subcellular sites may be related to CoV replication.

TMEM41B’s role in the formation of SARS-CoV-2 ROs was further explored. We found that after co-overexpression of NSP3 and NSP4 from SARS-CoV-2 in WT cells, the ER morphology was visibly swollen and distorted compared with that in mock cells (S12A–S12F Fig). Numerous ER membranes have obvious membrane curvatures, resulting in large deformations (S12E and S12F Fig). The result showed that SARS-CoV-2 non-structural proteins (NSPs) can induce small DMVs with a diameter of ~100 nm in HEK293T cells (S12G–S12L Fig), which coincides with previous reports on Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV [50]. By contrast, we found that the ER morphology has no obvious swelling or deformation after co-expression of NSP3 and NSP4 in TMEM41B KO cells (S12G–S12L Fig). Lastly, we provided a hypothetical model for TMEM41B’s role in CoV replication (Fig 5J) and speculated that this gene may be involved in membrane bending during RO formation.

TMEM41B is an essential host factor for the replication of numerous viruses from different families

Multiple sequence alignment of human, pig, and mouse TMEM41B orthologs showed striking conservation, especially in the VTT domain (Fig 6A). We hence examined the potential effects of TMEM41B on mice MHV infection in TMEM41B KO and its reconstituted L929 cells. Compared with the WT group, the supernatant virus titers of the TMEM41B KO L929 cells significantly decreased as measured in 50% tissue culture toxicity dose assays (TCID50 assay), while the virus replication can be restored on TMEM41B-KO-rescue cells (Fig 6B). We also found that porcine deltacoronavirus (PDCoV) replication was significantly inhibited in TMEM41B KO cells compared with that in WT cells (Fig 6C) as demonstrated by the reduced supernatant virus titers of the TMEM41B KO cells in the TCID50 assay.

Fig 6. TMEM41B is a host factor for the replication of multiple viruses.

Fig 6

(A) Alignment of TMEM41B amino acid sequences from pigs, human and mice. The accession Numbers of TMEM41B from NCBI protein database for Sus scrofa is XP_003129438.1 (pTMEM41B), for Homo sapiens is NP_055827.1 (hTMEM41B), and for Mus musculus is NP_705745.3 (mTMEM41B). Protein sequences were aligned using Constraint-based Multiple Alignment Tool (COBALT). The dark star indicates the regions of sequence conservation amongst the three species (letters indicated in red); the blue letters indicate the regions with sequence variation among the three species; the box indicates the VTT domain. (B) Rescue assays for WT, TMEM41B-KO and TMEM41B-KO-rescue L929 cells infected with MHV (MOI = 0.1, 24 hpi). Cell supernatant was collected and assessed for MHV titers using TCID50. (C-F) Rescue assays for WT, TMEM41B-KO and TMEM41B-KO-rescue PK-15 cells infected with (C) PDCoV (MOI = 0.01, 18 hpi), (D) JEV (MOI = 0.1, 24hpi), (E) IAV-PR8 (MOI = 0.01, 24 hpi) and (F) VSV (MOI = 0.01, 18 hpi). The cell supernatant was collected and tittered using TCID50 assays and immunofluorescence assays to detect NP positive cells. (G) Viral titers for TMEM41B-KO, TMEM41B/IFNAR double KO and TMEM41B/IFNAR double KO-TMEM41B-rescue cells infected with VSV (MOI = 0.1, 18 hpi) and cell supernatants was collected and titrated using TCID50. (H) Immunofluorescence assays for TMEM41B-KO, TMEM41B/IFNAR double KO and TMEM41B/IFNAR double KO-TMEM41B-rescue cells infected with IAV (MOI = 0.1, 18 hpi) and detection the NP positive cells. WT, wild-type; KO, knockout; hpi, hours post-infection; MHV, Mouse hepatitis virus; PDCoV, porcine deltacoronavirus; JEV, Japanese encephalitis virus; IAV-PR8, PR8 influenza A virus; VSV, Vesicular stomatitis virus. **P < 0.01; ***P < 0.001; ****P <0.0001. P values were determined by two-sided Student’s t-test. Data are representative of at least three independent experiments.

Additional assays showed that TMEM41B reduced the replication ability of positive-strand RNA viruses, including porcine JEV (Flaviviridae) (Fig 6D). We observed that TMEM41B KO led to significantly inhibited replication of the negative-strand RNA virus, PR8 influenza A virus (IAV-PR8, H1N1) (Fig 6E) and vesicular stomatitis virus (VSV) (Fig 6F). In addition, TMEM41B KO and TMEM41B/IFNAR double KO and WT cells were infected with VSV. The results showed that the VSV infectious titer in double KO cells was ~1 log higher than that of TMEM41B KO cells. However, rescue TMEM41B in the TMEM41B/IFNAR double KO cells further increased VSV replication compared with that in the TMEM41B/IFNAR double KO cells. This result suggested that the upregulation of ISG level in TMEM41B KO cells only partially inhibit VSV replication, suggesting that TMEM41B may participate in VSV replication through other mechanisms (Fig 6G). In comparison, the replication of IAV increased significantly in the TMEM41B/IFNAR double KO cells compared with that in the TMEM41B KO cells (Fig 6H). Meanwhile, rescue TMEM41B in the TMEM41B/IFNAR double KO cells does not facilitate further IAV replication. This result indicated that the upregulation of ISG level in TMEM41B KO cells may be the main factor inhibiting IAV replication. These results revealed that TMEM41B is an essential host factor for the replication of various RNA viruses.

TMEM41B is required for CoV infection in vivo

To determine whether knocking out TMEM41B affects the ability of α-CoV to replicate in vivo, TMEM41B KO mice were generated using CRISPR/Cas9 technology. Two sgRNAs were employed to delete the region spanning Exons 2 to 5 of the TMEM41B gene (S13A Fig). However, consistent with other studies reporting TMEM41B as an essential component for mouse embryonic development [54], we were only able to obtain heterozygous TMEM41B KO mice (S13B–S13E Fig). In heterozygous KO mice (TMEM41B+/−), the TMEM41B mRNA levels were reduced by approximately 60% in liver tissue (S13F Fig). The impairment of autophagic flux characterized by p62 accumulation was significantly increased in the liver and kidney of TMEM41B+/− mice compared with that in WT mice. This result suggested that autophagic activity was disturbed in TMEM41B+/− mice (S13G Fig). In addition, the serum lipid concentrations, including those of triglyceride, total cholesterol, and low-density lipoprotein cholesterol, in the serum of TMEM41B+/− mice decreased significantly compared with those in WT mice (S13H Fig). The results indicated that TMEM41B+/− mice may have defective on lipid transport, which is consistent with a previous study [55].

Subsequently, TMEM41B+/− and WT mice (approximately 4 weeks old, n = 6) were intraperitoneally injected with MHV-A59 (plaque-forming units, p.f.u. = 5 × 105). The control groups received an equal volume of Dulbecco’s Modified Eagles Medium Media (DMEM) by the same route. Each mouse’s weight was monitored daily, and lethality was recorded. The body weight change of TMEM41B+/− mice infected with CoV MHV-A59 significantly declined compared with those of WT mice (Fig 7A and 7B). We further found that TMEM41B+/− mice had significantly delayed disease progression compared with WT mice upon MHV-A59 challenge (Fig 7C). Compared with the livers of MHV-infected WT mice, TMEM41B+/− mice significantly alleviated liver tissue necrosis and damage caused by MHV infection (Fig 7D). Histopathological analysis showed extensive necrotic areas in WT mice livers but only focal necrosis loci in TMEM41B+/− mice livers (Fig 7E). Measurement of the viral titers in TMEM41B+/− and WT livers showed that the virus titers of TMEM41B+/− mice livers were significantly reduced compared with those of WT mice livers (Fig 7F). These results revealed that TMEM41B is involved in CoV MHV infection in vivo.

Fig 7. TMEM41B is required for CoVs infection in vivo.

Fig 7

(A) Line graphs showing the body weight of TMEM41B+/− and WT mice during the 3 days post-inoculation with MHV A59 (n = 6 mice per genotype). *P < 0.05; **P < 0.01; ***P < 0.001; ns, no significant. P-values were determined by two-way measure. (B) The total weight change of TMEM41B+/− and WT mice during the 3 days post-inoculation of MHV A59 (n = 6 mice per genotype). **P < 0.01; ns, no significant. P-values were determined by one-way measure. (C) Survival curves for TMEM41B+/− and WT mice infected with MHV A59 (n = 6 mice per genotype). (D and E) Histopathological analysis of the degree of liver damage in TMEM41B+/− and WT mice infection with MHV A59 at 3 dpi. (D) Gross postmortem examination of liver tissue; (E) histological examination of Hematoxylin-eosin (H&E) stained liver tissue. (F) The virus titers of half livers of TMEM41B+/− and WT mice were measured TCID50 assay with L929 cells (n = 3 mice per genotype). **P < 0.01. P values were determined by two-sided Student’s t-test. (G) A model illustrating the roles of TMEM41B in the CoV replication cycle. In WT cells, CoV binds to its receptor and enters through clathrin- and caveolin-mediated endocytosis before releasing their genome into the cytoplasm after membrane fusion in the early/late endosome. Subsequently, CoVs Nsps (NSP3, NSP4, and NSP6) act with TMEM41B and other transmembrane host proteins in the formation of ROs. In TMEM41B KO cells, endocytosis is impaired, and the internalization of virions was reduced. Moreover, the formation of DMVs was blocked during membrane elongation leading to the inhibition of TGEV replication so that almost no virions were produced. DMVs, double-membrane vesicles; ER, Endoplasmic reticulum; Mock, uninfected mice; MHV-A549, A549 Mouse hepatitis virus infected mice. WT, wild-type; KO, knockout; TMEM41B+/− mice used in Fig 7 were the F2 generation. Data are representative of at least three independent experiments. Source data are provided as a Source Data file. The experiments were repeated three times with similar results and representative results shown. Scale bar, 200 nm.

Discussion

Emerging CoVs pose a severe threat to human and animal health worldwide. Additional studies investigating the replication mechanisms of CoVs, which can potentially identify novel targets for developing drugs to treat CoV infections, are urgently needed. The present study used a PigGeCKO library and identified host factors involved in TGEV replication in host cells. The known cell-surface receptor of TGEV (i.e., ANPEP) was among the identified factors [31,32]. We also screened candidate host factors, including TMEM41B and DYRK1A, both of which were also reported from SARS-CoV-2 screenings [27,28,56]. Moreover, experimental validation of hits from our CRISPR screen demonstrated that numerous candidate host factors participated in TGEV replication. We found that TMEM41B functions in the replication of α-, β-, and δ-group CoVs. Several studies have shown that TMEM41B is involved in the replication of members of the human CoVs, such as SARS-CoV-2, HCov-229E, and HCov-NL63 [27,28,56,57]. However, the regulatory mechanism of TMEM41B in CoV replication remains unclear. In the present study, we systematically studied the possible conservative mechanism of TMEM41B in CoV replication. Moreover, our animal experiments demonstrated the functional relevance of TMEM41B for CoV infection in vivo for the first time. We found that upon MHV-A59 infection, TMEM41B+/− mice had significantly delayed disease progression and had significantly reduced virus titers.

We found that TMEM41B confers cell susceptibility to virus entry (Fig 4A–4C) and cell permissively for CoV replication (Fig 4G and 4H). Although virion internalization level on TMEM41B KO cells were reduced, numerous virions successfully internalized into the cytoplasm (Fig 4C). However, we found that the internalized virions were unable to further replicate in TMEM41B KO cells (Fig 4G and 4H). The results strongly indicated that the replication stage of the virus depends the most on TMEM41B and may be the most biologically relevant stage. Our result was consistent with that of another report that showed that SARS-CoV-2 replication in cells lacking TMEM41B was reduced by more than 80% when the entry step was bypassed [28]. Moreover, the TEM assay result showed that knocking out TMEM41B to inhibit CoV replication was related to CoV DMV formation (Fig 4A–4F).

DMVs offer a conducive microenvironment for viral RNA synthesis and shield viral RNA from innate immune sensors that are activated by dsRNA [22]. Although the viral factors involved in the formation of CoV DMVs are already known, the host factors involved in DMV formation remain largely unknown. Here, we found that TMEM41B can co-localize with CoV NSP3 (Fig 5G), and in response to CoV infection, the subcellular location of TMEM41B co-localizes with dsRNA, thereby participating in CoV replication. These results suggested that TMEM41B is recruited to participate in virus replication, potentially via interactions with NSPs of CoVs. A previous study demonstrated that TMEM41B co-localizes and co-immunoprecipitates with the nonstructural protein 4A (NS4A) and NS4B proteins of yellow fever virus and Zika virus; TMEM41B was found to be recruited to flavivirus RNA replication complexes to facilitate membrane curvature [58]. The present study supported the hypothesis that with the lack of TMEM41B, CoVs NSPs do not have sufficient membrane curvature to generate the DMVs (S12 Fig). Thus, we suggest that TMEM41B may represent a conserved host factor for the replication of CoVs and other positive-strand RNAs.

In the process of revising the present paper, we found several studies that revealed that TMEM41B acts as a phospholipid scramblase mediating trans-bilayer shuttling of phospholipids [55,59,60]. Combined with our new findings, we speculate that TMEM41B’s role in DMV formation is as follows (Fig 5J): TMEM41B may mediate the phospholipids synthesized on the cytoplasmic leaflets and shuttle to the luminal leaflets to promote the phospholipid bilayer’s balance. When cells are infected by a CoV, the transmembrane proteins of NSPs (i.e., NSP3, NSP4, and NSP6) encoded by the virus located in the ER are oligomerized and recruit TMEM41B to increase membrane curvature, thereby leading to DMV formation. However, TMEM41B’s defect can prevent the CoV-encoded NSPs from modifying the ER membrane curvature to generate DMV (Fig 5J). Overall, the ER scramblase TMEM41B can be recruited to promote ER deformation to consequently promote CoV RO formation.

Interestingly, we found that TMEM41B is an intrinsic negative regulator of cellular innate immunity, which has not been reported in other papers. A previous study reported TMEM41B as an ER-resident protein that localizes at mitochondria-associated ER membranes (MAMs) [54], which are known to be functionally specialized contact sites; MAMs have been recognized as necessary for diverse biological processes, including calcium homeostasis, autophagy [61], and the mediation of intracellular immune synapses which direct antiviral innate immunity [62]. The functions of TMEM41B are thus related to intracellular innate immunity and may be related to its localization at MAMs. In addition, autophagy was found to be a homeostatic process with several effects on immunity [63]. Autophagy represents an anti-inflammatory mechanism in its engagement with inflammasomes, and their substrates protect against endomembrane damage triggered by various agents of endogenous or infectious origin and prevent unnecessary or excessive inflammation [64,65]. The absence of autophagy may also amplify DDX58/RIG-I-like receptor signaling through increased mitochondrial antiviral signaling protein levels on accumulating mitochondria [66]. Therefore, the impaired autophagy pathway on TMEM41B KO cells may trigger excessive innate immunity.

Perhaps the most striking finding from the present study is that TMEM41B KO cells displayed broad-spectrum antiviral effects on other viruses, including the positive-strand RNA virus JEV and the negative-strand RNA viruses IAV and VSV. Our results revealed that IAV is highly sensitive to the upregulated expression of ISGs in TMEM41B KO cells. However, knocking out TMEM41B not only inhibits VSV infection by regulating ISGs. The VSV infection requires normal host lipid metabolism [67]. Several studies have shown that lipid transport is impaired in TMEM41B KO cells [36,57,68]. Whether knocking out TMEM41B may inhibit lipid transport and thereby inhibit VSV infection remain unclear.

In summary, we proposed a hypothetical model to illustrate TMEM41B’s roles in the CoV replication cycle. As shown in Fig 7G, after CoV infects host cells and binds to the receptor, CoV enters the cell through endocytosis and then releases its genome into the cytoplasm after early/late endosomal membrane fusion. Subsequently, CoV NSP3 acts with TMEM41B and other transmembrane host proteins in DMV formation. By contrast, the endocytosis of TMEM41B KO cells is impaired, resulting in a reduction in internalized CoV particles. In addition, DMV formation in TMEM41B KO cells is blocked, resulting in the inhibition of CoV replication in host cells. Our findings collectively indicated that TMEM41B is a bona fide host factor for CoV replication and emphasized the strong potential of TMEM41B as a therapeutic target for developing (possibly broad-spectrum) drugs to inhibit the replication of emerging and re-emerging CoVs.

Materials and methods

Ethics statement

All experiments involving mice were performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the Ministry of Science and Technology of China and were approved by the Scientific Ethics Committee of Huazhong Agricultural University (permit number: HZAUMO-2020-0051). Animal care and maintenance protocols complied with the recommendations detailed in the Regulations for the Administration of Affairs Concerning Experimental Animals crafted by the Ministry of Science and Technology of China.

Plasmid construction

To construct the lentivirus sgRNA expression vector, the lenti-sgRNA-EGFP vector [30] was digested by the BbsI restriction enzyme. The paired oligonucleotides of sgRNA were annealed and cloned into the linearized vector. To construct the overexpression vector for the rescue experiments, the coding sequences of TMEM41B were cloned into the pcDNA3.1(+) vector (Invitrogen) which was linearized with NheI and KpnI by In-Fusion HD Cloning Plus (Clontech). To construct the overexpression vector for the generation of TMEM41B stable cell lines, the coding sequences of TMEM41B were cloned into the pLVX-T2A-mCherry-Puro vector (Clontech) which was linearized with XhoI and BamHI. Subsequently, to abolish cleavage by sgRNA and Cas9 in TMEM41B KO cells, a specific point mutation in protospacer adjacent motif sequences, which does not alter the amino acid, was introduced into the TMEM41B coding sequences to construct its mutant overexpression vectors. Sanger sequencing (Tsingke) was performed to confirm all plasmids. All primer sequences are listed in S4 Data.

Cell culture and transfection

PK-15, HEK293T, and BHK-21 cell lines were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). ST (CRL-1746) and L929 (CCL-1) cell lines were purchased from ATCC (USA). All cell lines were then subjected to mycoplasma detection. For cell culture experiments in the present study, all cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 μg/mL streptomycin, and incubated at 37°C with 5% CO2. All cell transfections were performed with JetPRIME (PolyPlus) reagent according to the manufacturer’s instructions. WT and candidate gene KO PK-15 cells with approximately 80% confluency were first seeded into 12-well plates and transfected with 1 μg plasmid DNA. At 24 h after transfection, cells were incubated with TGEV. At 8 h after incubation, the inoculum was removed and replaced with 1 mL of fresh DMEM containing 10% FBS and 1% penicillin–streptomycin. After 24 h of incubation, immunofluorescence assays and RT-qPCR assays were conducted.

Viruses

The following viruses were used: TGEV WH-1 strain (GenBank accession numbers: HQ462571.1), MHV A59 strain (GenBank accession numbers: MF618253.1), IAV PR8 strain (GenBank accession numbers: AGQ48042.1), and PDCoV strain CHN-HN-2014 (GenBank accession number: KT336560). VSV and Pseudorabies virus (PRV) were provided by Prof. Gang Cao, and JEV P3 strain was obtained from Prof. Min Cui at Huazhong Agricultural University. TGEV, PSV, VSV, and PRV were propagated in PK-15 cells. JEV and IAV were propagated in Baby Hamster Kidney Fibroblast Cells (BHK-21 line) and chicken embryos, respectively.

Focused-CRISPR library design and construction

A focused-CRISPR library was designed on the basis of the results of three TGEV challenge rounds of genome-wide CRISPR screening. First, 6–7 sgRNAs were designed against each enriched candidate gene from the top 79 ranked sgRNAs from the third and fifth TGEV challenge rounds (S2 Data). Next, the focused-CRISPR library was synthesized using CustomArray 12K arrays (CustomArray Inc.). Oligonucleotide pools were amplified by PCR using Phusion High-Fidelity PCR Master Mix with HF Buffer (NEB). The PCR products were purified and cloned into the linearized lenti-sgRNA-EGFP vector via Gibson assembly approach. To ensure sufficient coverage, more than 2 × 105 transformants were collected to generate a plasmid library of sgRNAs.

sgRNA library lentivirus production

Co-transfection of 12 μg of the PigGeCKO or focused-CRISPR library plasmid, 4 μg of pMD2.G plasmid (Addgene, #12259), and 8 μg of psPAX2 (Addgene, #12260) plasmid per 100-mm dish was performed by using JetPRIME (PolyPlus) according to the manufacturer’s instructions. At 60 h after transfection, the cell supernatants were collected, filtered by using a 0.45 μm low-protein binding membrane (Millipore), and then centrifuged at 30,000 rpm and 4°C for 2.5 h. The lentivirus pellets were resuspended in DMEM solution, aliquoted, and stored at −80°C.

Construction of PigGeCKO cells and focused-CRISPR KO cells and TGEV challenge

The PigGeCKO cells were generated by a total of ~2 × 108 PK-15-Cas9 cells and infected with the genome-wide sgRNA library lentiviruses at an MOI of 0.3 as described in a previous publication [30]. In addition, the focused-CRISPR KO cells were generated by a total of ~2 × 107 PK-15-Cas9 cells and infected with the focused-CRISPR sgRNA library lentiviruses. To examine the coverage of PigGeCKO cells and focused-CRISPR KO cells, genomic DNA (gDNA) from a total of ~7 × 106 cells were extracted using Blood & Cell Culture DNA Midi Kit (QIAGEN). For the genome-wide CRISPR screening assays, ~6 × 107 PigGeCKO cells were infected with TGEV at an MOI of 0.001 in DMEM without FBS and incubated at 37°C and 5% CO2. For focused-CRISPR screening assays, ~1 × 107 focused-CRISPR KO cells were infected with TGEV at an MOI of 1. After 2 h of incubation, the inoculum was removed and replaced with fresh DMEM supplemented with 2% FBS and 1% penicillin–streptomycin. At 7 days after infection, surviving cells were collected and expanded for deep sequencing analysis and the next round of infection.

Illumina sequencing of sgRNAs in the PigGeCKO cells and focused-CRISPR KO cells

The gDNA from the surviving PigGeCKO cells and focused-CRISPR KO cells were first extracted using a Blood & Cell Culture DNA Midi Kit (QIAGEN). The sgRNA-coding region was amplified by PCR using Q5 Hot Start High-Fidelity DNA Polymerase (NEB). PCR products were purified using MinElute PCR Purification Kit (QIAGEN) followed by Illumina HiSeq 3000 Next-generation Sequencing. Mapped read counts were subsequently used as input for the MAGeCK analysis software package (Version 0.5) [69]. The top 0.5% ranked sgRNAs from each TGEV challenge round were then used to identify enriched targeted protein-coding genes. All primers are listed in S4 Data.

Generation of candidate gene KO cell lines

sgRNA targeted candidate genes were cloned into the linearized lenti-sgRNA-EGFP, and lentivirus containing sgRNAs were produced as described in a previous study [30]. The sgRNA lentivirus was then transduced into PK-15-Cas9 cells. On the third day after transduction, cells with GFP expression were enriched by fluorescence-activated cell sorting. Editing efficiency was examined using Tracking of Indels by Decomposition (TIDE) program [70]. All primers are listed in S4 Data.

RT-qPCR

Total RNA from cells and viral RNAs from cell suspensions were extracted with the TRIzol Reagent (Invitrogen). Complementary DNAs (cDNAs) were synthesized using PrimeScript RT Reagent Kit with gDNA Eraser (TaKaRa) in a total volume of 10 μL. Each RT-qPCR reaction was carried out with 100 ng of cDNA and 5 nM primer pairs by using SYBR Green Mix (Bio-Rad, USA). The results were monitored using a CFX96 Real-Time PCR Detection System (Bio-Rad, USA) programmed for one cycle of 15 min at 95°C, followed by 39 cycles of 10 s at 95°C and 30 s at 60°C. The relative expression levels were calculated using 2−△△Ct method. Beta-actin gene was used as a normalization control. For absolute RT-qPCR, approximately 1 μL of viral RNAs was used as template to synthesize cDNAs. Absolute RT-qPCR assays were performed using SYBR Green Mix and primers specific for the N gene of TGEV in a final reaction volume of 10 μL. The TGEV N protein-coding cDNA sequence from GenBank (accession number: ADY39745.1) was cloned into the pcDNA3.1 vector and used as an internal reference for the quantification of TGEV copy numbers. All primers used in quantitative PCR are listed in S4 Data.

Virus plaque assay and virus titers

Crystal violet assays were performed as follows: WT and TMEM41B KO PK-15 cells were first incubated in a 24-well plate with different MOIs of TGEV at 37°C with 5% CO2. The plates were incubated for 1 h and swirled every 15 min to ensure complete infection, after which the inoculum was removed and the cells were overlaid with 50% 2× DMEM, 50% Low Melting Point Agarose (Gibco), 10% FBS, and 1% penicillin–streptomycin for 2 days. The plates were then fixed with 4% formaldehyde for 1 h and stained with 1% crystal violet. Virus titers were performed as follows: Confluent monolayers of different candidate gene KO cells and control cells in 12-well plates were inoculated with TGEV in triplicate at an MOI of 1. The cell supernatants were harvested at 24 hpi, and the virus titers were determined by the TCID50 assays using PK-15 cells.

Immunofluorescence assay

The protein expression levels of TGEV N protein in candidate gene KO cells and control cells were determined via an immunofluorescence assay. Cells grown on the 12-well cell culture plates were first infected with TGEV at different MOIs. At 24 hpi, cells were fixed with 4% paraformaldehyde at room temperature for 30 min and then permeabilized at room temperature for 10 min with cold 0.3% TritonX-100 in phosphate buffered saline (PBS). Cells were incubated with TGEV N antibody (A rabbit anti-TGEV N protein polyclonal antibody was prepared in our laboratory) or anti-dsRNA antibody (SCICONS, #10010200, 1:1,000) at 4°C overnight, and the primary antibodies were recognized by Alexa Fluor 594 Goat anti-Mouse IgG (H+L) (Invitrogen, #A-11005, 1:1,000), Alexa Fluor 594 Anti-Rabbit IgG (H + L) (Invitrogen, #A-11012, 1:1,000), or Alexa Fluor Plus 647 Goat anti-Mouse IgG (H+L) (Invitrogen, #A32728, 1:1,000). Cell nuclei were counterstained with 4’, 6-diamidino-2-phenylindole (DAPI) (Sigma, #D9542) at room temperature for 1 min in the dark. Cells were observed and imaged with a fluorescence microscope (Thermo Fisher Scientific EVOS FL Auto). The proportion of positive cells were calculated using Image J software (three independent wells were imaged, and one random field of view per well was captured for each experimental phase).

Immunoblotting assay

To detect the presence of TGEV N protein, total cell lysates were prepared by lysing WT and TMEM41B KO PK-15 cells in 10× sample buffer. Proteins were separated by SDS-PAGE and transferred onto polyvinylidene fluoride membranes (Millipore). Membranes were blocked using 5% skim milk powder (Merck) in PBS with 0.1% Tween-20 (Bio-rad) and blotted with an antibody against TGEV N protein (1:1,000). GAPDH antibodies (Beyotime, #AF5009, 1:3,000) were used as an internal loading control. The primary antibodies were detected with horseradish peroxidase conjugated goat anti-rabbit IgG (Abclonal, #AS014, 1:3,000) or goat anti-mouse IgG (Beyotime, #A0216, 1:1,000), and the secondary antibodies were visualized by ECL Prime Western Blotting Detection Reagents (GE Healthcare, UK).

MTS and EdU cell proliferation assay

To assess cell proliferation, MTS and EdU cell proliferation assays were performed. The MTS assay was performed using MTS Assay Kit (Abcam, #ab197010). TMEM41B KO PK-15 cells and control cells were seeded into 96-well plates and incubated for 12 or 24 h. Afterward, 20 μL/well MTS reagent was added into each well and incubated at 37°C for 4 h in standard culture conditions. The plate was briefly shaken, and the absorbance of treated and untreated cells was measured using a plate reader at an optical density (OD) of 490 nm.

For the EdU assay, TMEM41B KO PK-15 cells and control cells were seeded into 24-well plates. After 24 h of incubation, the EdU cell proliferation assay was performed using BeyoClick EdU Cell Proliferation Kit (Beyotime, #C0075S) with Alexa Fluor 555 according to instruction. The cell nuclei were stained with DAPI (Beyotime, #C1005) at room temperature for 10 min in the dark. Stained cells were visualized under a fluorescence microscope. The proportion of EdU-positive cells was calculated using Image J software (three independent wells were imaged, and one random field of view per well was captured for each experimental phase).

TEM assay

TMEM41B KO and WT PK-15 cells were infected with TGEV at an MOI of 1 for 12 h. The cells were washed twice with pre-cooled PBS and fixed by adding 3 mL of 2.5% glutaraldehyde (Servicebio) at room temperature for 2 h. After fixation, cells were scraped and transferred into a 2 mL centrifuge tube. Negative-staining electron microscopy was performed by Servicebio company, and images were taken using an HZAU transmission electron microscope platform (HITACHI, #H-7650).

RNA sequencing and transcriptome analysis

For high-throughput RNA-seq, RNA libraries were created from each group, such as TMEM41B KO cells (i.e., TMEM41B_KO_MOCK, TMEM41B_KO_TGEV) and WT cells (i.e., WT_MOCK, WT_TGEV). Three replicates were conducted for each sample. poly(A) + RNA isolation, library construction, and sequencing were performed by the sequencing platform of the National Key Laboratory of Crop Genetic Improvement using MGISEQ-2000RS. Sequence quality for all samples was assessed using FastQC (v0.11.7), and quality trimming was conducted using FASTX-Toolkit (v 0.0.14) to remove bases with a Phred33 score of less than 30 while retaining the resulting reads of at least 50 bases in length. The quality trimmed reads were mapped against the reference genome of Sus scrofa (v11.1) using HISAT2 (v2.1.0). Gene expression profiling was performed on the basis of the number of reads. Fragments per kilo base of exon model per million mapped reads (FPKM) values of each unigene were used to estimate the expressed values and transcript levels by using SAMtools (v1.7) and HTSeq-count (v0.9.1). Differentially expressed genes (DEGs) were obtained by DESeq2 (v1.30.1) with a P-value cutoff ≦ 0.05 and an absolute fold-change of ≧ 1. Subsequently, DEGs in different pairwise groups were analyzed by PPI network (https://string-db.org/) and GSEA [71]. Furthermore, the PPI network of the selected DEGs was visualized using Cytoscape [72].

PolyI:C stimulation assay

For the PolyI:C stimulation assay, 2 × 105 PK-15-TMEM41B cells and control cells were incubated overnight in 500 μL cell culture media in 24-well plates. Cells were then incubated with fresh culture media containing PolyI:C (10 μg/mL, InvivoGen, #Tlrl-pic). At 24 hpi, the total RNA from cells was extracted based on previous measure. Relative expression levels of ISGs were detected by RT-qPCR and calculated using the 2−△△Ct method. All primers used are listed in S4 Data.

Confocal microscopy

To observe the endocytosis of the TGEV in host cells, the same amount of TMEM41B KO cells and control cells were cultured in 35-mm Petri dishes overnight. The equivalent dose of TGEV (MOI = 50) was added to each well and incubated at 4°C for 60 min for complete adsorption and then transferred to 37°C and incubated for 30 min for endocytosis. Immunofluorescence assays were performed as described above, while the images were acquired using a laser scanning confocal microscope (Nikon). The subcellular localization of TMEM41B in TMEM41B KO cells and control cells transfected with TMEM41B-FLAG-pCDNA3.1 plasmid was observed after 24 h. Afterward, TGEV (MOI = 1) was added into these cells, incubated for 24 h, immunolabeled with a FLAG-tag antibody (Proteintech, #20543-1-AP; MBL, #PM020) and dsRNA antibody, and imaged to identify double fluorescent positive cells. The co-localization of TMEM41B and TGEV NSP3 in TMEM41B KO cells was co-transfected with TMEM41B-FLAG-pCDNA3.1, and TGEV-NSP3-pCAGGS plasmids for 24 h was also observed. These cells were immunolabeled with anti-FLAG-tag and anti-HA-tag antibodies (Proteintech, #66006-1-Ig) and imaged for double-positive fluorescent cells.

Generation of TMEM41B KO mice and MHV challenge

The TMEM41B KO mice in the C57BL/6 genetic background were generated by Cyagen (China). To generate KO mice, a gDNA fragment spanning Exons 2 to 5 of TMEM41B was deleted by co-injecting sgRNAs and Cas9 mRNA into fertilized mouse eggs. The founders were genotyped by PCR amplification of gDNA extracted from mouse tails, followed by Sanger sequencing. WT and TMEM41B KO mice (approximately 4 weeks old, n = 6) were subjected to intraperitoneal injection with MHV-A59 (p.f.u. = 5 × 105). The control group received an equal volume of DMEM via the same strategy. The weight of each mouse was monitored daily, and the lethality was recorded. The mock and virus-infected mice were sacrificed at the indicated days after infection to observe the liver’s pathology. Liver sections were fixed in buffered formalin (4%) solution, embedded in paraffin, and sectioned into 4 μm tissue sections. Sections were stained with Hematoxylin and Eosin, examined, and imaged under a light microscope. Livers were homogenized in 1 mL of DMEM and centrifuged at 8,000 rpm for 10 min at 4°C. The virus titers in the supernatants were collected and measured via TCID50 assays with PK-15 cells. P62 protein expression was detected through the following steps: 0.1 g livers and kidney tissues of TMEM41B+/− and WT mice were homogenized in 1 mL RIPA Lysis Buffer (Beyotime, P0013), and the homogenate was crushed by ultrasonication for 1 min. The homogenate was centrifuged at 12,000 rpm for 30 min at 4°C. Subsequently, the supernatant was collected for Western blot.

Supporting information

S1 Fig. Determination of the optimal infection dose of TGEV-induced PK-15 cell death.

The red boxes indicate TGEV-induced cytopathic effects (CPE) in PK-15 cells infected with TGEV at MOIs of 0.001, 0.01, 0.1, or 1. The mock was non-infected TGEV cells used as a negative control. Scale bar, 200 μm. MOI, multiplicity of infection; dpi, days post-infection; TGEV, Transmissible gastroenteritis virus.

(TIF)

S2 Fig

DNA sequence analysis showing the presence of the mutation in clonal KO cells of TMEM41B (A), ANPEP (B), LPP (C), TAX1BP1 (D), and BARHL2 (E). The underline indicates the deleted bases in the KO cells. The black box indicates the PAM sites. PAM: protospacer adjacent motif; sgRNA, small guide RNA; WT, wild-type; KO, knockout; del, deletion; bp, base pairs.

(TIF)

S3 Fig. Knockout of TMEM41B does not affect the proliferation of PK-15 cells.

(A) Design of CRISPR-resistant pTMEM41B sequences. To abolish cleavage by sgRNA and Cas9 in TMEM41B KO cells, a specific point mutation in PAM sequence, which does not alter the amino acid was introduced into the TMEM41B coding sequences. (B) There was no significant change in the proportion of EdU positive cells in clonal TMEM41B KO cell lines compared to WT cells. Left: representative pictures. Right: quantification of EdU positive cells. Quantitative analysis of immunofluorescence was used by Image J software. (C) TMEM41B KO and PK-15 WT cells were seeded into 96-well plates to evaluate cell proliferation by MTS assays at 12 hpi and 24 hpi. Scale bar, 200 μm. Data are represented as means ± S.D.; n = 3, ns: no significant. pTMEM41B, porcine TMEM41B gene; WT, wild-type; KO, knockout; PAM, protospacer adjacent motif; hpi, hours post-infection; DAPI, 4’,6-diamidino-2-phenylindole. ns, no significant. P values were determined by two-sided Student’s t-test.

(TIF)

S4 Fig. TMEM41B KO ST cells show inhibited TGEV replication.

(A) WT cells and VMP1 KO PK-15 cells were infected with TGEV (MOI = 1) for 24h and used for immunofluorescence assays. Left: representative pictures. Right: quantification of TGEV N positive cells. Quantitative analysis of immunofluorescence was conducted with Image J software. Scale bar, 400 μm. (B) WT cells and TMEM41A KO PK-15 cells were infected with TGEV (MOI = 1) for 24h and used for qRT-PCR to measure the TGEV N copy number. (C) WT cells and TMEM41B KO ST cells were infected with TGEV (MOI = 1) for 24 h and used for qRT-PCR to measure TGEV N copy number. WT, wild-type; KO, knockout; DAPI, 4’,6-diamidino-2-phenylindole; ST, porcine Sertoli cells. **P < 0.001; ns, no significant. P values were determined by two-sided Student’s t-test.

(TIF)

S5 Fig. The canonical autophagy pathway does not participate in inhibiting TGEV replication.

(Left) Western blot analysis of LC3-I and LC3-II in untreated WT and ATG5 KO cells; (Middle) Western blot analysis of LC3-I and LC3-II in WT and ATG5 KO cells after EBSS medium (EBSS) starvation and E64d supplementation for 6 h; (Right) Western blot analysis of TGEV N in WT and ATG5 KO cells following infection with TGEV (MOI = 1) at 12 hpi. GAPDH was shown as a loading control. WT, wild-type; KO, knockout; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TGEV, Transmissible gastroenteritis virus infected cells; Mock, uninfected cells; E64D, aloxistatin; ATG5, autophagy related gene 5.

(TIF)

S6 Fig. Protein-protein interaction (PPI) network of the selected DEGs visualized with Cytoscape (WT-MOCK vs. WT-TGEV).

Differentially expressed genes in the "interferon signaling" pathway were marked with yellow. WT, wild-type; TGEV, Transmissible gastroenteritis virus infected cells; Mock, uninfected cells.

(TIF)

S7 Fig. Protein-protein interaction (PPI) network of the selected DEGs visualized with Cytoscape (TMEM41B-KO-MOCK vs. TMEM41B-KO-TGEV).

Differentially expressed genes in the "interferon signaling" pathway were marked with yellow. KO, knockout; TGEV, Transmissible gastroenteritis virus infected cells; Mock, uninfected cells.

(TIF)

S8 Fig. Protein-protein interaction (PPI) network of the selected DEGs visualized with Cytoscape (WT-MOCK vs. TMEM41B-KO-MOCK).

Differentially expressed genes in the "interferon signaling" pathway were marked with yellow. WT, wild-type; KO, knockout; Mock, uninfected cells.

(TIF)

S9 Fig. Protein-protein interaction (PPI) network of the selected DEGs visualized with Cytoscape (WT-TGEV vs. TMEM41B-KO-TGEV).

Differentially expressed genes in the "interferon signaling" pathway were marked with yellow. WT, wild-type; KO, knockout; TGEV, Transmissible gastroenteritis virus infected cells.

(TIF)

S10 Fig. Evaluation of the ability of TMEM41B to regulate the expression of ISGs in different types of cells.

(A and C) DNA sequence analysis showed that the presence of the mutation in (A) HEK293T and (C) L929 single clone originated TMEM41B KO cells. (B and D) Detection of mRNA expression of the ISGs in (B) TMEM41B-KO HEK293T and (D) TMEM41B-KO L929 cells by RT-qPCR. sgRNA, small guide RNA; PAM, protospacer adjacent motif; bp, base pairs; ins, insertion; del, deletion; WT, wild-type; KO, knockout. *P < 0.05; **P < 0.01; ***P < 0.001. P values were determined by two-sided Student’s t-test. Data are representative of at least three independent experiments.

(TIF)

S11 Fig. TMEM41B is a negative regulator of cell-intrinsic immunity.

(A-E) mRNA levels of the ISGs (A) MX1, (B) OASL, (C) IFIT1, (D) IFI6 and (E) RASD2 on PK-15 cells or PK-15 cells overexpressing TMEM41B with or without PolyI:C stimulation. (F-H) mRNA levels of ISGs (F) IFIT1, (G) RASD2 and (H) OASL in TMEM41B and IFNAR double KO cells were reduced to WT levels compared with TMEM41B KO cells. Data are representative of at least three independent experiments. NTC, negative control; PolyI:C, Polyinosinic: polycytidylic acid; WT, wild-type; KO, knockout. *P < 0.05; **P < 0.01; ***P < 0.001; ns, no significant. P values were determined by two-sided Student’s t-test. Data are representative of at least three independent experiments.

(TIF)

S12 Fig. Knockout TMEM41B inhibits the formation of DMVs induced by NSP3 and NSP4 from SARS-CoV-2.

(A) Schematic illustration of the backbone of SARS-CoV-2 Nsps plasmids. First, we generated TMEM41B KO HEK293T cell lines. Subsequently, we constructed PLV-mCherry-SARS-CoV-2-NSP3 and PLV-eGFP-SARS-CoV-2-NSP4 lentiviral expression vectors. After co-infection of PLV-mCherry-SARS-CoV-2-NSP3 and PLV-eGFP-SARS-CoV-2-NSP4 lentivirals in TMEM41B KO and WT HEK293T cells, the double immunofluorescence cells (mCherry and eGFP) were sorted by flow cytometer. (B-F) (B) HEK293T MOCK-treated cells and (C-F) SARS-CoV-2 NSP3 and NSP4 co-expressed cells were fixed for TEM analysis. (C) DMVs and (D-F) large deformation of ER can be observed. Red arrows indicate curved ERs. (G-H) HEK293T-TMEM41B-KO MOCK treatment cells (G and H) and SARS-CoV-2 NSP3 and NSP4 co-expressed cells (I-L) were fixed for TEM analysis. Mock, untreated control cells; +SARS2-CoV2-NSP3, NSP4, co-overexpression of NSP3 and NSP4 from SARS-CoV-2; WT, wild-type; KO, knockout; M, Mitochondria; ER, Endoplasmic reticulum; N, Nucleus; LD, lipid droplet; A, autophagosome; LTR, long terminal repeat; CMV, cytomegalovirus promoter; WPRE, Woodchuck Hepatitis Virus (WHP) Posttranscriptional Regulatory Element; GFP; green fluorescent protein; mCherry, mCherry fluorescent protein. Mock, uninfected cells.

(TIF)

S13 Fig. The generation and characterization of TMEM41B-deficient mice.

(A) A schematic diagram of generation of F2 TMEM41B-deficient mice. (B and C) There was no significant morphological difference between F2 generation TMEM41B+/− mice and WT (C57BL/6N) mice. (D) Genotyping of F2 generation TMEM41B+/− mice using genomic DNA from tail clips. (E) Sanger sequencing of PCR products from F2 generation TMEM41B+/−mice. (F) The relative TMEM41B gene expression level of F2 generation TMEM41B+/− mice liver tissue was reduced by about 70% compared with WT mice liver tissue. (G) Western blot assays analysis the autophagy maker p62 protein of liver and kidney tissue from WT and TMEM41B+/− mice with starvation treatment. (H) The serum lipid concentrations of WT and TMEM41B+/− mice (before MHV infection) were measured by corresponding reagent kit: TG (Rayto, S03027); CHO (Rayto, S03042); HDL (Rayto, S03025); LDL (Rayto, S03029). F, forward primer; R, reverse primer; WT, wild-type; NC, negative control; del, deletion, E1-7, exons from 1 to 7; bp, base pairs; M, DNA marker; sgRNA, small guide RNA; F0, founder generation mice; F1, F1 generation mice; F2, F2 generation mice; TG, triglyceride; CHO, cholesterol; HDL, High-density lipoprotein; LDL, Low-density lipoprotein. *P < 0.05; **P < 0.01; ***P < 0.001; ns, no significant. P values were determined by two-sided Student’s t-test. Data are representative of at least three independent experiments.

(TIF)

S1 Data. Sequencing results of sgRNAs (PigGeCKO) in each of three rounds of TGEV screening after challenge.

(XLSX)

S2 Data. Sequencing results of sgRNAs (Focused-CRISPR library) in the third and fifth rounds of TGEV screening after challenge.

(XLS)

S3 Data. Differential gene expression analysis derived from RNA-seq.

(XLSX)

S4 Data. Primer pairs and sgRNA targeting sequences used in this study.

(XLSX)

Acknowledgments

We thank the following investigators for contributing viral stocks: Prof. Hongbo Zhou (IAV PR8), Prof. Min Cui (JEV P3), Prof. Gang Cao (VSV and PRV), Prof. Shaobo Xiao (PDCoV: KT366560). We thank Dr. Yan Wang (Institute of Hydrobiology, Chinese Academy of Sciences) for her assistance with flow cytometry.

Data Availability

Raw sequencing data and processed counts data for sgRNA libraries that support the findings of this study have been deposited in National Center for Biotechnology Information’s Gene Expression Omnibus and are accessible through GEO Series accession number: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE169113.

Funding Statement

This work was supported by the National Natural Science Foundation of China (grants No.: 31873020, to GQP), China National Funds of Distinguished Young Scientists (grants No.: 32125037, to GQP), and National Natural Science Foundation of China (grants No.: 32072685, to SSX). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Gonzalez JM, Gomez-Puertas P, Cavanagh D, Gorbalenya AE, Enjuanes L. A comparative sequence analysis to revise the current taxonomy of the family Coronaviridae. Arch Virol. 2003;148(11):2207–35. doi: 10.1007/s00705-003-0162-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193–292. doi: 10.1016/S0065-3527(06)66005-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3. doi: 10.1038/s41586-020-2012-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Laude H, Rasschaert D, Delmas B, Godet M, Gelfi J, Charley B. Molecular biology of transmissible gastroenteritis virus. Vet Microbiol. 1990;23(1–4):147–54. doi: 10.1016/0378-1135(90)90144-k [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Moon HW, Norman JO, Lambert G. Age dependent resistance to transmissible gastroenteritis of swine (TGE). I. Clinical signs and some mucosal dimensions in small intestine. Can J Comp Med. 1973;37(2):157–66 [PMC free article] [PubMed] [Google Scholar]
  • 6.Hirano N, Murakami T, Taguchi F, Fujiwara K, Matumoto M. Comparison of mouse hepatitis virus strains for pathogenicity in weanling mice infected by various routes. Arch Virol. 1981;70(1):69–73. doi: 10.1007/BF01320795 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Houtman JJ, Fleming JO. Pathogenesis of mouse hepatitis virus-induced demyelination. J Neurovirol. 1996;2(6):361–76. doi: 10.3109/13550289609146902 [DOI] [PubMed] [Google Scholar]
  • 8.Lavi E, Gilden DH, Wroblewska Z, Rorke LB, Weiss SR. Experimental demyelination produced by the A59 strain of mouse hepatitis virus. Neurology. 1984;34(5):597–603. doi: 10.1212/wnl.34.5.597 [DOI] [PubMed] [Google Scholar]
  • 9.Badawy AA. Liver tryptophan 2,3-dioxygenase in the mouse hepatitis virus (MHV-A59) model. Immunol Lett. 2020;225:23–4. doi: 10.1016/j.imlet.2020.05.007 [DOI] [PubMed] [Google Scholar]
  • 10.De Albuquerque N, Baig E, Ma X, Zhang J, He W, Rowe A, et al. Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice. J Virol. 2006;80(21):10382–94. doi: 10.1128/JVI.00747-06 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res. 2011;81:85–164. doi: 10.1016/B978-0-12-385885-6.00009-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Yang Z, Du J, Chen G, Zhao J, Yang X, Su L, et al. Coronavirus MHV-A59 infects the lung and causes severe pneumonia in C57BL/6 mice. Virol Sin. 2014;29(6):393–402. doi: 10.1007/s12250-014-3530-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, Pohlmann S. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A. 2005;102(22):7988–93. doi: 10.1073/pnas.0409465102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–4. doi: 10.1038/nature02145 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–4. doi: 10.1038/nature12005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Yeager CL, Ashmun RA, Williams RK, Cardellichio CB, Shapiro LH, Look AT, et al. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature. 1992;357(6377):420–2. doi: 10.1038/357420a0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Huang IC, Bosch BJ, Li W, Farzan M, Rottier PM, Choe H. SARS-CoV, but not HCoV-NL63, utilizes cathepsins to infect cells: viral entry. Adv Exp Med Biol. 2006;581:335–8. doi: 10.1007/978-0-387-33012-9_60 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol. 2012;86(12):6537–45. doi: 10.1128/JVI.00094-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kawase M, Shirato K, Matsuyama S, Taguchi F. Protease-mediated entry via the endosome of human coronavirus 229E. J Virol. 2009;83(2):712–21. doi: 10.1128/JVI.01933-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Wicht O, Li W, Willems L, Meuleman TJ, Wubbolts RW, van Kuppeveld FJ, et al. Proteolytic activation of the porcine epidemic diarrhea coronavirus spike fusion protein by trypsin in cell culture. J Virol. 2014;88(14):7952–61. doi: 10.1128/JVI.00297-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Hagemeijer MC, Rottier PJ, de Haan CA. Biogenesis and dynamics of the coronavirus replicative structures. Viruses. 2012;4(11):3245–69. doi: 10.3390/v4113245 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Knoops K, Kikkert M, Worm SH, Zevenhoven-Dobbe JC, van der Meer Y, Koster AJ, et al. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol. 2008;6(9):e226. doi: 10.1371/journal.pbio.0060226 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. Host Factors in Coronavirus Replication. Curr Top Microbiol Immunol. 2018;419:1–42. doi: 10.1007/82_2017_25 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Miao X, Luo Y, Huang X, Lee SMY, Yuan Z, Tang Y, et al. A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy. MAbs. 2020;12(1):1804241. doi: 10.1080/19420862.2020.1804241 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Wolff G, Limpens R, Zevenhoven-Dobbe JC, Laugks U, Zheng S, de Jong AWM, et al. A molecular pore spans the double membrane of the coronavirus replication organelle. Science. 2020;369(6509):1395–8. doi: 10.1126/science.abd3629 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Shittu MO, Afolami OI. Improving the efficacy of Chloroquine and Hydroxychloroquine against SARS-CoV-2 may require Zinc additives—A better synergy for future COVID-19 clinical trials. Infez Med. 2020;28(2):192–7. . [PubMed] [Google Scholar]
  • 27.Wei J, Alfajaro MM, DeWeirdt PC, Hanna RE, Lu-Culligan WJ, Cai WL, et al. Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection. Cell. 2021;184(1):76–91 e13. doi: 10.1016/j.cell.2020.10.028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Schneider WM, Luna JM, Hoffmann HH, Sanchez-Rivera FJ, Leal AA, Ashbrook AW, et al. Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks. Cell. 2021;184(1):120–32 e14. doi: 10.1016/j.cell.2020.12.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Li B, Clohisey SM, Chia BS, Wang B, Cui A, Eisenhaure T, et al. Genome-wide CRISPR screen identifies host dependency factors for influenza A virus infection. Nat Commun. 2020;11(1):164. doi: 10.1038/s41467-019-13965-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Zhao C, Liu H, Xiao T, Wang Z, Nie X, Li X, et al. CRISPR screening of porcine sgRNA library identifies host factors associated with Japanese encephalitis virus replication. Nat Commun. 2020;11(1):5178. doi: 10.1038/s41467-020-18936-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Delmas B, Gelfi J, L’Haridon R, Vogel LK, Sjostrom H, Noren O, et al. Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus TGEV. Nature. 1992;357(6377):417–20. doi: 10.1038/357417a0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Luo L, Wang S, Zhu L, Fan B, Liu T, Wang L, et al. Aminopeptidase N-null neonatal piglets are protected from transmissible gastroenteritis virus but not porcine epidemic diarrhea virus. Sci Rep. 2019;9(1):13186. doi: 10.1038/s41598-019-49838-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Morita K, Hama Y, Mizushima N. TMEM41B functions with VMP1 in autophagosome formation. Autophagy. 2019;15(5):922–3. doi: 10.1080/15548627.2019.1582952 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Morita K, Hama Y, Izume T, Tamura N, Ueno T, Yamashita Y, et al. Genome-wide CRISPR screen identifies TMEM41B as a gene required for autophagosome formation. J Cell Biol. 2018;217(11):3817–28. doi: 10.1083/jcb.201804132 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Shoemaker CJ, Huang TQ, Weir NR, Polyakov NJ, Schultz SW, Denic V. CRISPR screening using an expanded toolkit of autophagy reporters identifies TMEM41B as a novel autophagy factor. PLoS Biol. 2019;17(4):e2007044. doi: 10.1371/journal.pbio.2007044 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Moretti F, Bergman P, Dodgson S, Marcellin D, Claerr I, Goodwin JM, et al. TMEM41B is a novel regulator of autophagy and lipid mobilization. EMBO Rep. 2018;19(9). doi: 10.15252/embr.201845889 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Mizushima N, Yoshimori T, Ohsumi Y. The role of Atg proteins in autophagosome formation. Annu Rev Cell Dev Biol. 2011;27:107–32. doi: 10.1146/annurev-cellbio-092910-154005 [DOI] [PubMed] [Google Scholar]
  • 38.Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732–8. doi: 10.1038/35099560 [DOI] [PubMed] [Google Scholar]
  • 39.den Boon JA, Ahlquist P. Organelle-like membrane compartmentalization of positive-strand RNA virus replication factories. Annu Rev Microbiol. 2010;64:241–56. doi: 10.1146/annurev.micro.112408.134012 . [DOI] [PubMed] [Google Scholar]
  • 40.Mackenzie J. Wrapping things up about virus RNA replication. Traffic. 2005;6(11):967–77. doi: 10.1111/j.1600-0854.2005.00339.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Miller S, Krijnse-Locker J. Modification of intracellular membrane structures for virus replication. Nat Rev Microbiol. 2008;6(5):363–74. doi: 10.1038/nrmicro1890 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.den Boon JA, Diaz A, Ahlquist P. Cytoplasmic viral replication complexes. Cell Host Microbe. 2010;8(1):77–85. doi: 10.1016/j.chom.2010.06.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Gosert R, Kanjanahaluethai A, Egger D, Bienz K, Baker SC. RNA replication of mouse hepatitis virus takes place at double-membrane vesicles. J Virol. 2002;76(8):3697–708. doi: 10.1128/jvi.76.8.3697-3708.2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Snijder EJ, van der Meer Y, Zevenhoven-Dobbe J, Onderwater JJ, van der Meulen J, Koerten HK, et al. Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex. J Virol. 2006;80(12):5927–40. doi: 10.1128/JVI.02501-05 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Ulasli M, Verheije MH, de Haan CA, Reggiori F. Qualitative and quantitative ultrastructural analysis of the membrane rearrangements induced by coronavirus. Cell Microbiol. 2010;12(6):844–61. doi: 10.1111/j.1462-5822.2010.01437.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Avila-Perez G, Rejas MT, Rodriguez D. Ultrastructural characterization of membranous torovirus replication factories. Cell Microbiol. 2016;18(12):1691–708. doi: 10.1111/cmi.12620 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Nakatogawa H. Mechanisms governing autophagosome biogenesis. Nat Rev Mol Cell Biol. 2020;21(8):439–58. doi: 10.1038/s41580-020-0241-0 . [DOI] [PubMed] [Google Scholar]
  • 48.Reggiori F, Monastyrska I, Verheije MH, Cali T, Ulasli M, Bianchi S, et al. Coronaviruses Hijack the LC3-I-positive EDEMosomes, ER-derived vesicles exporting short-lived ERAD regulators, for replication. Cell Host Microbe. 2010;7(6):500–8. doi: 10.1016/j.chom.2010.05.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Rubinsztein DC, Shpilka T, Elazar Z. Mechanisms of autophagosome biogenesis. Curr Biol. 2012;22(1):R29–34. doi: 10.1016/j.cub.2011.11.034 . [DOI] [PubMed] [Google Scholar]
  • 50.Oudshoorn D, Rijs K, Limpens R, Groen K, Koster AJ, Snijder EJ, et al. Expression and Cleavage of Middle East Respiratory Syndrome Coronavirus nsp3-4 Polyprotein Induce the Formation of Double-Membrane Vesicles That Mimic Those Associated with Coronaviral RNA Replication. mBio. 2017;8(6). doi: 10.1128/mBio.01658-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Angelini MM, Akhlaghpour M, Neuman BW, Buchmeier MJ. Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles. mBio. 2013;4(4). doi: 10.1128/mBio.00524-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Clementz MA, Kanjanahaluethai A, O’Brien TE, Baker SC. Mutation in murine coronavirus replication protein nsp4 alters assembly of double membrane vesicles. Virology. 2008;375(1):118–29. doi: 10.1016/j.virol.2008.01.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Snijder EJ, Limpens R, de Wilde AH, de Jong AWM, Zevenhoven-Dobbe JC, Maier HJ, et al. A unifying structural and functional model of the coronavirus replication organelle: Tracking down RNA synthesis. PLoS Biol. 2020;18(6):e3000715. doi: 10.1371/journal.pbio.3000715 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Van Alstyne M, Lotti F, Dal Mas A, Area-Gomez E, Pellizzoni L. Stasimon/Tmem41b localizes to mitochondria-associated ER membranes and is essential for mouse embryonic development. Biochem Biophys Res Commun. 2018;506(3):463–70. doi: 10.1016/j.bbrc.2018.10.073 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Huang D, Xu B, Liu L, Wu L, Zhu Y, Ghanbarpour A, et al. TMEM41B acts as an ER scramblase required for lipoprotein biogenesis and lipid homeostasis. Cell Metab. 2021;33(8):1655–70 e8. doi: 10.1016/j.cmet.2021.05.006 . [DOI] [PubMed] [Google Scholar]
  • 56.Wang R, Simoneau CR, Kulsuptrakul J, Bouhaddou M, Travisano KA, Hayashi JM, et al. Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses. Cell. 2021;184(1):106–19 e14. doi: 10.1016/j.cell.2020.12.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Trimarco JD, Heaton BE, Chaparian RR, Burke KN, Binder RA, Gray GC, et al. TMEM41B is a host factor required for the replication of diverse coronaviruses including SARS-CoV-2. PLoS Pathog. 2021;17(5):e1009599. doi: 10.1371/journal.ppat.1009599 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Hoffmann HH, Schneider WM, Rozen-Gagnon K, Miles LA, Schuster F, Razooky B, et al. TMEM41B Is a Pan-flavivirus Host Factor. Cell. 2021;184(1):133–48 e20. doi: 10.1016/j.cell.2020.12.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Li YE, Wang Y, Du X, Zhang T, Mak HY, Hancock SE, et al. TMEM41B and VMP1 are scramblases and regulate the distribution of cholesterol and phosphatidylserine. J Cell Biol. 2021;220(6). doi: 10.1083/jcb.202103105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Ghanbarpour A, Valverde DP, Melia TJ, Reinisch KM. A model for a partnership of lipid transfer proteins and scramblases in membrane expansion and organelle biogenesis. Proc Natl Acad Sci U S A. 2021;118(16). doi: 10.1073/pnas.2101562118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Vance JE. MAM (mitochondria-associated membranes) in mammalian cells: lipids and beyond. Biochim Biophys Acta. 2014;1841(4):595–609. doi: 10.1016/j.bbalip.2013.11.014 . [DOI] [PubMed] [Google Scholar]
  • 62.Namgaladze D, Khodzhaeva V, Brune B. ER-Mitochondria Communication in Cells of the Innate Immune System. Cells. 2019;8(9). doi: 10.3390/cells8091088 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Deretic V, Levine B. Autophagy balances inflammation in innate immunity. Autophagy. 2018;14(2):243–51. doi: 10.1080/15548627.2017.1402992 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Shi CS, Shenderov K, Huang NN, Kabat J, Abu-Asab M, Fitzgerald KA, et al. Activation of autophagy by inflammatory signals limits IL-1beta production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol. 2012;13(3):255–63. doi: 10.1038/ni.2215 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469(7329):221–5. doi: 10.1038/nature09663 . [DOI] [PubMed] [Google Scholar]
  • 66.Tal MC, Sasai M, Lee HK, Yordy B, Shadel GS, Iwasaki A. Absence of autophagy results in reactive oxygen species-dependent amplification of RLR signaling. Proc Natl Acad Sci U S A. 2009;106(8):2770–5. doi: 10.1073/pnas.0807694106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Wang W, Fu YJ, Zu YG, Wu N, Reichling J, Efferth T. Lipid rafts play an important role in the vesicular stomatitis virus life cycle. Arch Virol. 2009;154(4):595–600. doi: 10.1007/s00705-009-0348-2 . [DOI] [PubMed] [Google Scholar]
  • 68.Kang ZB, Moutsatsos I, Moretti F, Bergman P, Zhang X, Nyfeler B, et al. Fluopack screening platform for unbiased cellular phenotype profiling. Sci Rep. 2020;10(1):2097. doi: 10.1038/s41598-020-58861-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 2014;15(12):554. doi: 10.1186/s13059-014-0554-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Brinkman EK, Chen T, Amendola M, van Steensel B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014;42(22):e168. doi: 10.1093/nar/gku936 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50. doi: 10.1073/pnas.0506580102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Otasek D, Morris JH, Boucas J, Pico AR, Demchak B. Cytoscape Automation: empowering workflow-based network analysis. Genome Biol. 2019;20(1):185. doi: 10.1186/s13059-019-1758-4 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Sabra L Klein, Mark T Heise

21 Jun 2021

Dear Dr. Guiqing,

Thank you very much for submitting your manuscript " Genome-scale CRISPR screen identifies TMEM41B as a multi-function host factor required for coronavirus replication " for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

As noted by the reviewers, there are a number of experimental and methodological details that are missing that must be addressed. Concerns about distinctions between virus internalization and replication must be clarified. The points raised by Reviewer 1 are particularly insightful, including addressing inconsistencies in TGEV replication in TMEM41B KO cells. The reviewers request additional experimentation that would be required for reconsideration.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Sabra L. Klein

Associate Editor

PLOS Pathogens

Mark Heise

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************

As noted by the reviewers, there are a number of experimental and methodological details that are missing that must be addressed. Concerns about distinctions between virus internalization and replication must be clarified. The points raised by Reviewer 1 are particularly insightful, including addressing inconsistencies in TGEV replication in TMEM41B KO cells. The reviewers request additional experimentation that would be required for reconsideration.

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: Multiple independent studies using genome-wide CRISPR-Cas9 screens have identified TMEM41B as playing critical roles in autophagy and lipid mobilization. Subsequent screens to identify host factors required for viral replication identified TMEM41B as important for the replication of diverse coronaviruses and flaviviruses.

The authors extend the requirement of TMEM41B to a member of the Alphacoronavius family, TGEV, in a different host organism, Sus scrofa (Pig). Their findings are mostly in line with those previously reported in Hoffmann et al 2021. Novel findings from this study include the in vivo work and a potentially interesting association between TMEM41B and innate immune regulation. This manuscript is the first to demonstrate the functional relevance of TMEM41B and coronavirus disease pathogenesis in vivo. The authors propose a novel function for TMEM41B in regulating the innate immune response, however, additional evidence is needed to substantiate this function of TMEM41B.

Reviewer #2: This thorough submission presents results indicating that TMEM41B renders cells and experimental mice permissive to coronavirus infection. The study follows a standard path, from CRISPR KO screening, to identification and validation of TMEM41B as necessary for robust growth of virus, to focus toward mechanism of TMEM41B operations in virus infection cycles.

If there is a central issue, it is that very similar results have been published. The most strikingly similar work was published while this work was submitted, it is and https://doi.org/10.1371/journal.ppat.1009599 and so it is in the PPATH now. However, there may be good arguments for having some duplicated work in the journal.

The new findings in this submission are that (1) the TMEM41B suppresses interferon signaling, but this is not the proviral TMEM41B mechanism; (2) the TMEM41B is claimed to facilitate virus endocytosis; (3) the TMEM41B increases C57BL/6 mouse susceptibility to lethal MHV A59 infection. The main findings that TMEM41B is needed for post-entry replicative processes and that TMEM41B facilitates virus replication organelles are also present. These main findings concord with the previous publications on TMEM41B in flavivirus and coronavirus replication.

Reviewer #3: This manuscript reports the identification of TMEM41B as a host factor required for the infection of the transmissible gastroenteritis virus (TGEV), a member of α-coronaviruses. The authors show that TMEM41B is important for the formation of double-membrane vesicles that are derived from the ER and required for viral replication. The authors suggest that TMEM41B also protects mice from coronaviral (MHV) infection.

In general, it is important to search for host factors required for viral infections. However, at least six genome-wide CRISPR screening studies (one published in PLOS pathogens) have so far identified TMEM41B as a host factor of coronaviral infection, which reduces the novelty of this study. This study also provides potentially novel findings: (i) the effect of TMEM41B loss on the formation of double-membrane vesicles and (ii) the role of TMEM41B in mice in vivo. Unfortunately, the data of these two findings are not convincing enough in the present version (see specific comments below).

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: Major points

If TMEM41B is the primary cause of the TGEV replication defect observed in the TMEM41B KO cells, why is there still such a drastic difference in TGEV replication when TMEM41B expression is restored in KO cells? The authors should include an explanation as to why TGEV replication is not rescued in the TMEM41B reconstituted cells. See Figure 2g-j: The relative levels of TMEM41B expression between TMEM41B-KO-rescue (figure 2g) and PK-15-overexpression (figure 2j) look comparable (relative to WT-NTC and PK-15-NTC, respectively) yet the TGEV mRNA detected in the RT-qPCR looks to differ by around 4 logs (figure 2h and j). TMEM41B-KO-rescue cells had 3 logs less TGEV mRNA detected relative to the WT-NTC (figure 2h)

The above point highlights the lack of information in the Methods section. For example, how did the authors perform the reconstitution experiments? From the Methods it seems that the KO clone constitutively expresses an sgRNA targeting TMEM41B. Did the authors mutate the TMEM41B cDNA so that it is resistant to cleavage? If the TMEM41B cDNA was reconstituted in cells expressing the TMEM41B sgRNA it could explain the partial rescue observed in the TMEM41B-KO-rescue cells.

The nomenclature in the manuscript is confusing. The authors use WT and PK-15 and it seems these may be the same but it is unclear. For example, what is the difference between figure 2g and 2i? In supplementary figure 10, overexpression of TMEM41B in PK-15 cells potently inhibits ISG expression compared to PK-15/WT cells, even after treatment with polyIC. Therefore, lower levels of the ISG transcripts for WT compared to the TMEM41B KO-rescue cells for figure 3f is unexpected. For example, we can see this in supplementary figure 10d – IFIT1 expression is lower in the PK-15-overexpression cells compared to WT in the absence of polyIC treatment. This should be comparable to IFIT1 in figure 3f, however, higher IFIT1 expression is observed in the TMEM41B-KO-rescue relative to WT. It is impossible to see if this is the case for the rest of the ISGs in figure 10 given the scale of the y-axis.

Figure 6b-f: The striking ISG upregulation observed in the TMEM41B KO cells confounds the replication defect observed for these virus families. The antiviral state in TMEM41B KO cells, beyond the function of TMEM41B, makes it difficult to conclude that the defect is due to the requirement of TMEM41B and not a result of the higher basal ISG levels. The authors address this for TGEV by generating a double KO for TMEM41B and IFNAR, which normalized the ISG expression, and confirm that TGEV replication is still not supported. Therefore, the effects seen for these other viruses could be due to IFN/ISG expression. This is particularly important for understanding the replication defect seen in negative strand-viruses which was not observed in a previous study. It is also mechanistically unclear how negative-strand RNA virus replication would be affected given the proposed role of TMEM41B in replication organelle formation for positive-strand viruses. The inconsistency between their model and how the negative-strand RNA viruses are inhibited is not explained and experiments to address this are not included. These results need to be confirmed in the double KO IFNAR cell lines as done with TGEV. Reconstitution experiments with TMEM41B with these other viral families should also be performed to demonstrate TMEM41B’s role in their replication.

Overall, the manuscript is difficult to follow, makes some inaccurate claims, and overstates results. Significant rephrasing of many statements is needed.

A few examples of many:

It is unclear what is meant by the statement made in lines 265-266:

“Additionally, we observed the subcellular localization of restore expression of TMEM41B in its KO cells infect with or without TGEV.”

Inaccurate statement on lines 247-248:

“CoVs, like all positive-strand RNA viruses of eukaryotes, hijack intracellular ER membranes to form their RO.”

Not all positive-strand RNA viruses replicate on ER membranes.

Although the observation that TMEM41B is required for TGEV replication in pig cells has some novelty (i.e. first report of TMEM41B requirement for this particular virus and host species), previous studies have demonstrated the importance of TMEM41B for the replication of various flaviviruses and coronaviruses in human, bovine, and insect cell lines. A comparison of the results highlighting the similarities and differences between the previous reports and the authors findings is largely absent from the paper. Also, most of the unique findings presented in this paper, particularly the ISG upregulation, are significantly underdeveloped.

Reviewer #2: The work is generally solid but there are some comments on the data:

1. Fig. 4d, these data do not provide much confidence in the claim that TMEM41B facilitates virus endocytosis. The figure lacks images of virus particles bound at 4C but not yet internalized by shift to 37C. Given equivalent virus binding to TMEM41B+ and – cells (Fig 4a), one wonders where the viruses are located in TMEM41B-KO cells in Fig 4d.

2. Fig. 5A, it is hard to be sure that the red arrow is pointing to a replication organelle; also, more replication organelles should be imaged to get a better sense of the TMEM41B role in RO formation. Optimally, immunogold EM or similar methods should be used to identify TMEM41B in the ROs.

3. Fig. 5bcd, the TMEM41B and TGEV NSP3 proteins are so over-expressed that it is hard to make claims for relevant colocalization. The IFA signals cover most of the cytoplasm. A suggestion is to assess colocalization at lower expression levels (levels consistent with natural expression in infected cells).

Reviewer #3: 1. The data of knockout mice (Fig. 7) are potentially important but not convincing.

- It is not clear how many mice were used in the experiments in a, b, and f, and what statistical analysis was used in a and b (the t-test is not acceptable). Actual p-values should be shown.

- It is questionable that heterozygous mice indeed have a defect in the function of TMEM41B. Even though heterozygous mice express a reduced amount of TMEM41B, it may be sufficient physiologically. Thus, it is essential to determine whether some of the key functions (e.g., p62 accumulation, autophagic flux, lipid droplet accumulation, coronaviral replication, DMV formation) are indeed defective in cultured TMEM41B+/- cells. Also, the p62 level, lipid droplet accumulation, and serum lipid concentrations should be compared between Wild-type and TMEM41B+/- mice (before infection).

- The authors used 6 mice in the experiment in Panel C. How can there be a 20% reduction?

- The authors should indicate the generation (F0, F1, or F2 etc.) of the mice used in Fig. 7 and Sup. Fig. 11C-F.

- The description "TMEM41B-KO" is inappropriate. This should be "TMEM41B+/-".

2. The quality of the electron microscopy data is not good. The images are too small to evaluate. In Fig. 5a, "double membranes" are not visible. Images with higher resolution should be presented. In addition, some quantification is required in order to show that TMEM41B is required for the formation of double-membrane vesicles.

3. It is not clear how the authors distinguish between viral internalization and replication. They use essentially the same method at different time points. This reviewer is not sure whether this is sufficient.

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: Lines 119-120: “Our screen found that a total of 335 unique sgRNA sequences, which targeting to 317 unique protein-coding genes”

There seems to be no convergence of sgRNAs per gene identified in the screen – essentially one guide per gene. One would expect that with multiple sgRNAs targeting a single gene, there should be multiple sgRNAs enriched for each of the hits. This weakens the reliability of the screen data. Was the screen performed with replicates? At what fold-representation was the screen performed? There is no information about the full-genome screen in the Methods section.

Based on the results presented, TMEM41B was not the most reliable hit from the screens. What was the rationale for choosing TMEM41B as opposed to the other genes identified as top hits in the screen?

Figure 2f-j: What time point were the cells harvested at?

Figure 2g-j: What is the difference between WT-NTC and PK-15-NTC? If these are the same consistent naming would helpful.

Figure 3e and f: why are there such large discrepancies between the relative fold change between figures e and f? For example, there is 100-fold difference for MX1 when comparing WT and TMEM41B KO in figure 3e but only a 10-fold difference for MX1 in figure 3f. Would be nice to have an idea of the raw transcript numbers for these ISGs and see how this may influence the large fold changes observed in these experiments.

Figure 3: are there differences in IFN mRNA levels between the various cell lines? Does this change if TMEM41B is overexpressed?

Figure 3: Other cell lines should be tested to see the ISG upregulation observed in the TMEM41B KO cells is cell line specific. This would help to explain why their results differ from those previously reported.

Supplementary figure 10: It is surprising that the PK-15 cells overexpressing TMEM41B completely inhibits the upregulation of ISGs when treated with polyIC. Further work to show if this is polyIC specific or to help explain these results should be demonstrated.

Figure 4c: The low image resolution/magnification makes it impossible to state that no DMV formation is observed in the TMEM41B KO cells. We can see the absence of viral particles in the TMEM41B KO cells compared to the WT, but it cannot be determined from this image if DMVs are present.

Figure 4: The authors suggest viral endocytosis may contribute to the replication defect observed. It has been shown in other studies that when viral RNA is directly transfected into cells (bypassing endocytosis) a replication defect is still observed in TMEM41B KO cells. This highlights the need for Sun et al to compare their results to previous reports that used different viruses and host species and discuss the similarities and differences.

Reviewer #2: There are also some minor comments:

1. Fig. 1; consider highlighting the TMEM41B in panel b and d scatter plots

2. Fig. 4b, hard to be sure that the red arrows are pointing to virus particles (but evidence for less virus morphogenesis in TMEM41B-KO is strong from other results)

There are also some comments on the text:

1. The text has many confusing sentences, too many to itemize. Some examples include lines 94-100; this section summarizes results but does so in an awkward way. Authors would benefit from rephrasing this part. Lines 160-161; VTT domain is not in TGEV, it is in the TMEM41B related proteins. Rephrase this. Lines 200-202, requires rephrasing. Lines 221-222, this sentences is actually misleading and does not summarize the actual result, rephrase to emphasize that ratios of extra vs intra-cellular viral PFU are being assessed. Lines 374-375; requires rephrasing. There are more issues and there should be another go at revising the text.

2. The discussion section does not make any speculations on the roles that TMEM41B might have during minus strand RNA virus and DNA virus replication. Instead, there are only the statements on lines 388-390. There is an unrealized opportunity here.

Reviewer #3: 1. The recently identified role of TMEM41B as a lipid scramblase should be included in Discussion (doi: 10.1073/pnas.2101562118, doi: 10.1083/jcb.202103105, doi: 10.1016/j.cmet.2021.05.006).

2. Sequence IDs and alignment methods should be described in the legends or Methods.

3. Supplementary Fig. 5: Small but significant amounts of LC3-II are observed in ATG5-KO and ATG7-KO cells. These are not typical results, raising a concern that isolation of KO cells was not appropriate. Please carefully check them. Otherwise, the authors' claim that "the canonical autophagy pathway is not required for TGEV replication" (L184-185) is not valid.

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here on PLOS Biology: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Decision Letter 1

Sabra L Klein, Mark T Heise

24 Sep 2021

Dear Dr. Guiqing,

Thank you very much for submitting your manuscript "Genome-scale CRISPR screen identifies TMEM41B as a multi-function host factor required for coronavirus replication" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

Requests for data to be shown in the actual manuscript or supplementary files, instead of just mentioned in text or only shown in the response to the review are justified and should be fixed.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Sabra L. Klein

Associate Editor

PLOS Pathogens

Mark Heise

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************

Requests for data to be shown in the actual manuscript or supplementary files, instead of just mentioned in text or only shown in the response to the review are justified and should be fixed.

Reviewer Comments (if any, and for reference):

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #2: The authors responded strongly to previous reviews by providing additional results that significantly reinforce the key conclusions of the paper. They complemented TMEM41B KO cells with TMEM41B genes, did this properly, and this added important results demonstrating TMEM41B as a central virus permissively factor. They added new results that now show virus endocytosis and virus-induced DMVs at higher resolution, thereby supporting the contention that TMEM41B operates to support entry and DMV formation. They nicely illustrated distinct functions for TMEM41B in innate immune response, virus endocytosis, virus replication organelle formation, and in vivo virus infection in the liver. They included procedural details that now make it possible for readers to fully appreciate the experiments and results. They appropriately extended discussion of the findings and their contributions to the field.

Reviewer #3: The authors addressed most of my previous comments, but there remain some issues to be addressed.

Reviewer #4: The authors address many of the reviewer concerns in the revised manuscript. As before, the strengths of this manuscript include the in vivo work and the novel innate immune phenotype observed in the TMEM41B knockout (KO) PK-15 cells. The additional results with TMEM41B/IFNAR double KO PK-15 cells supports the role of TMEM41B in suppressing innate immune activation in PK-15 cells; however, as the authors point out, the effect is minor in other cell types. Indeed, the results in HEK293T and L929 cells are less convincing without additional controls. The ISG upregulation in TMEM41B KO cells may therefore not be generalizable to other cell types. Further, there is a missed opportunity to test other viruses in the TMEM41B/IFNAR1 double KO cells to rule out the possibility that reduced virus replication in TMEM41B KO cells results from elevated ISGs. Nevertheless, the innate immune signature in TMEM41B KO PK-15 cells will be of interest to the field and is worthy of further investigation. In the Discussion section, the authors may wish to speculate more on possible mechanisms by which TMEM41B regulates innate immunity.

Comments on revised manuscript

Major point 1:

The authors addressed the TMEM41B-KO-resuce by generating a stable single-clone cell line reconstituted with WT TMEM41B. They also include more detail on the methods used to generate the cell line.

TMEM41B is an intrinsic regulator of innate immunity

The authors also test human HEK293T and mouse L929 cell lines to determine if the innate immune regulation is observed in other cell types. These data are questionable without additional controls. The gene expression differences are minor and can easily be explained by clone-to-clone variability. As a result, it remains unclear if TMEM41B’s role in suppressing innate immunity is specific to PK-15 cells. Nevertheless, experiments conducted in this manuscript support the author’s claim of innate immune regulation by TMEM41B in PK-15 cells.

Major point 3:

The authors addressed the concern for figure 6B-G by testing the viruses in TMEM41B reconstituted cells and testing VSV in the TMEM41B/IFNAR double KO cell line. It would be nice to have conducted the TMEM41B reconstitution experiment in the TMEM41B/IFNAR double KO cell line since WT is not the best comparison after generating and growing out single cell clones (particularly after multiple rounds as would have been done for the double KO cell line). Again, there seems to be some missed opportunity here as the innate immune phenotype is one of the more interesting findings in the study. It leaves the reader to wonder how IAV infects the double KO cell line.

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #2: The opinion of this reviewer is that major issues have now been resolved and key experiments required for acceptance have now been completed.

Reviewer #3: Previous Major Point 1.

- The authors now show that the levels of serum lipids and tissue LC3-II are reduced (Fig. S13). Although the quantitative data of serum TG and LDL cholesterol levels are convincing, the authors’ claim that autophagic activity is reduced is not supported by these data. It has been shown that LC3-II rather accumulates in TMEM41B-/- cells (Ref #34-36). Therefore, the reduction of LC3-II in TMEM41B+/- tissues does not indicate autophagy suppression. Rather, it is actually the opposite. The authors have not included any other autophagic flux data (e.g., p62, LC3 turnover, GFP-RFP-LC3, etc.). Without such data, it would be fair to state that “while serum lipid levels are reduced, autophagic activity may not be affected in heterozygous mice”.

- The information of the number of mice and the method of statistics is still lacking in the legend to Fig. 7A, B and F. Please include.

Previous Major Point 2.

- The results of the quantification of DMVs should be shown in the manuscript, not only in the rebuttal letter.

Reviewer #4: (No Response)

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #2: 1. The authors have done a good job at determining whether TMEM41B confers cell susceptibility (virus entry, Figs 4AF) or cell permissively (virus replication, Fig 4GH and others). While they have not fully quantified the relative TMEM41B support for each step, the data point strongly to the replication stage being the one that is most dependent on TMEM41B, and likely the most biologically relevant stage. This could be emphasized in the discussion section.

2. Lines 318-327 are discussion points and belong there, not in the results section.

3. The text will need editing for syntax corrections.

4. The figures can be clarified by matching color codes between panels, i.e., in Fig 7 and several other figs.

Reviewer #3: (No Response)

Reviewer #4: (No Response)

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

Reviewer #4: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

References:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Decision Letter 2

Sabra L Klein, Mark T Heise

14 Nov 2021

Dear Dr. Guiqing,

We are pleased to inform you that your manuscript 'Genome-scale CRISPR screen identifies TMEM41B as a multi-function host factor required for coronavirus replication' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Sabra L. Klein

Associate Editor

PLOS Pathogens

Mark Heise

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************************************************

Reviewer Comments (if any, and for reference):

Acceptance letter

Sabra L Klein, Mark T Heise

29 Nov 2021

Dear Dr. Guiqing,

We are delighted to inform you that your manuscript, " Genome-scale CRISPR screen identifies TMEM41B as a multi-function host factor required for coronavirus replication ," has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Determination of the optimal infection dose of TGEV-induced PK-15 cell death.

    The red boxes indicate TGEV-induced cytopathic effects (CPE) in PK-15 cells infected with TGEV at MOIs of 0.001, 0.01, 0.1, or 1. The mock was non-infected TGEV cells used as a negative control. Scale bar, 200 μm. MOI, multiplicity of infection; dpi, days post-infection; TGEV, Transmissible gastroenteritis virus.

    (TIF)

    S2 Fig

    DNA sequence analysis showing the presence of the mutation in clonal KO cells of TMEM41B (A), ANPEP (B), LPP (C), TAX1BP1 (D), and BARHL2 (E). The underline indicates the deleted bases in the KO cells. The black box indicates the PAM sites. PAM: protospacer adjacent motif; sgRNA, small guide RNA; WT, wild-type; KO, knockout; del, deletion; bp, base pairs.

    (TIF)

    S3 Fig. Knockout of TMEM41B does not affect the proliferation of PK-15 cells.

    (A) Design of CRISPR-resistant pTMEM41B sequences. To abolish cleavage by sgRNA and Cas9 in TMEM41B KO cells, a specific point mutation in PAM sequence, which does not alter the amino acid was introduced into the TMEM41B coding sequences. (B) There was no significant change in the proportion of EdU positive cells in clonal TMEM41B KO cell lines compared to WT cells. Left: representative pictures. Right: quantification of EdU positive cells. Quantitative analysis of immunofluorescence was used by Image J software. (C) TMEM41B KO and PK-15 WT cells were seeded into 96-well plates to evaluate cell proliferation by MTS assays at 12 hpi and 24 hpi. Scale bar, 200 μm. Data are represented as means ± S.D.; n = 3, ns: no significant. pTMEM41B, porcine TMEM41B gene; WT, wild-type; KO, knockout; PAM, protospacer adjacent motif; hpi, hours post-infection; DAPI, 4’,6-diamidino-2-phenylindole. ns, no significant. P values were determined by two-sided Student’s t-test.

    (TIF)

    S4 Fig. TMEM41B KO ST cells show inhibited TGEV replication.

    (A) WT cells and VMP1 KO PK-15 cells were infected with TGEV (MOI = 1) for 24h and used for immunofluorescence assays. Left: representative pictures. Right: quantification of TGEV N positive cells. Quantitative analysis of immunofluorescence was conducted with Image J software. Scale bar, 400 μm. (B) WT cells and TMEM41A KO PK-15 cells were infected with TGEV (MOI = 1) for 24h and used for qRT-PCR to measure the TGEV N copy number. (C) WT cells and TMEM41B KO ST cells were infected with TGEV (MOI = 1) for 24 h and used for qRT-PCR to measure TGEV N copy number. WT, wild-type; KO, knockout; DAPI, 4’,6-diamidino-2-phenylindole; ST, porcine Sertoli cells. **P < 0.001; ns, no significant. P values were determined by two-sided Student’s t-test.

    (TIF)

    S5 Fig. The canonical autophagy pathway does not participate in inhibiting TGEV replication.

    (Left) Western blot analysis of LC3-I and LC3-II in untreated WT and ATG5 KO cells; (Middle) Western blot analysis of LC3-I and LC3-II in WT and ATG5 KO cells after EBSS medium (EBSS) starvation and E64d supplementation for 6 h; (Right) Western blot analysis of TGEV N in WT and ATG5 KO cells following infection with TGEV (MOI = 1) at 12 hpi. GAPDH was shown as a loading control. WT, wild-type; KO, knockout; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TGEV, Transmissible gastroenteritis virus infected cells; Mock, uninfected cells; E64D, aloxistatin; ATG5, autophagy related gene 5.

    (TIF)

    S6 Fig. Protein-protein interaction (PPI) network of the selected DEGs visualized with Cytoscape (WT-MOCK vs. WT-TGEV).

    Differentially expressed genes in the "interferon signaling" pathway were marked with yellow. WT, wild-type; TGEV, Transmissible gastroenteritis virus infected cells; Mock, uninfected cells.

    (TIF)

    S7 Fig. Protein-protein interaction (PPI) network of the selected DEGs visualized with Cytoscape (TMEM41B-KO-MOCK vs. TMEM41B-KO-TGEV).

    Differentially expressed genes in the "interferon signaling" pathway were marked with yellow. KO, knockout; TGEV, Transmissible gastroenteritis virus infected cells; Mock, uninfected cells.

    (TIF)

    S8 Fig. Protein-protein interaction (PPI) network of the selected DEGs visualized with Cytoscape (WT-MOCK vs. TMEM41B-KO-MOCK).

    Differentially expressed genes in the "interferon signaling" pathway were marked with yellow. WT, wild-type; KO, knockout; Mock, uninfected cells.

    (TIF)

    S9 Fig. Protein-protein interaction (PPI) network of the selected DEGs visualized with Cytoscape (WT-TGEV vs. TMEM41B-KO-TGEV).

    Differentially expressed genes in the "interferon signaling" pathway were marked with yellow. WT, wild-type; KO, knockout; TGEV, Transmissible gastroenteritis virus infected cells.

    (TIF)

    S10 Fig. Evaluation of the ability of TMEM41B to regulate the expression of ISGs in different types of cells.

    (A and C) DNA sequence analysis showed that the presence of the mutation in (A) HEK293T and (C) L929 single clone originated TMEM41B KO cells. (B and D) Detection of mRNA expression of the ISGs in (B) TMEM41B-KO HEK293T and (D) TMEM41B-KO L929 cells by RT-qPCR. sgRNA, small guide RNA; PAM, protospacer adjacent motif; bp, base pairs; ins, insertion; del, deletion; WT, wild-type; KO, knockout. *P < 0.05; **P < 0.01; ***P < 0.001. P values were determined by two-sided Student’s t-test. Data are representative of at least three independent experiments.

    (TIF)

    S11 Fig. TMEM41B is a negative regulator of cell-intrinsic immunity.

    (A-E) mRNA levels of the ISGs (A) MX1, (B) OASL, (C) IFIT1, (D) IFI6 and (E) RASD2 on PK-15 cells or PK-15 cells overexpressing TMEM41B with or without PolyI:C stimulation. (F-H) mRNA levels of ISGs (F) IFIT1, (G) RASD2 and (H) OASL in TMEM41B and IFNAR double KO cells were reduced to WT levels compared with TMEM41B KO cells. Data are representative of at least three independent experiments. NTC, negative control; PolyI:C, Polyinosinic: polycytidylic acid; WT, wild-type; KO, knockout. *P < 0.05; **P < 0.01; ***P < 0.001; ns, no significant. P values were determined by two-sided Student’s t-test. Data are representative of at least three independent experiments.

    (TIF)

    S12 Fig. Knockout TMEM41B inhibits the formation of DMVs induced by NSP3 and NSP4 from SARS-CoV-2.

    (A) Schematic illustration of the backbone of SARS-CoV-2 Nsps plasmids. First, we generated TMEM41B KO HEK293T cell lines. Subsequently, we constructed PLV-mCherry-SARS-CoV-2-NSP3 and PLV-eGFP-SARS-CoV-2-NSP4 lentiviral expression vectors. After co-infection of PLV-mCherry-SARS-CoV-2-NSP3 and PLV-eGFP-SARS-CoV-2-NSP4 lentivirals in TMEM41B KO and WT HEK293T cells, the double immunofluorescence cells (mCherry and eGFP) were sorted by flow cytometer. (B-F) (B) HEK293T MOCK-treated cells and (C-F) SARS-CoV-2 NSP3 and NSP4 co-expressed cells were fixed for TEM analysis. (C) DMVs and (D-F) large deformation of ER can be observed. Red arrows indicate curved ERs. (G-H) HEK293T-TMEM41B-KO MOCK treatment cells (G and H) and SARS-CoV-2 NSP3 and NSP4 co-expressed cells (I-L) were fixed for TEM analysis. Mock, untreated control cells; +SARS2-CoV2-NSP3, NSP4, co-overexpression of NSP3 and NSP4 from SARS-CoV-2; WT, wild-type; KO, knockout; M, Mitochondria; ER, Endoplasmic reticulum; N, Nucleus; LD, lipid droplet; A, autophagosome; LTR, long terminal repeat; CMV, cytomegalovirus promoter; WPRE, Woodchuck Hepatitis Virus (WHP) Posttranscriptional Regulatory Element; GFP; green fluorescent protein; mCherry, mCherry fluorescent protein. Mock, uninfected cells.

    (TIF)

    S13 Fig. The generation and characterization of TMEM41B-deficient mice.

    (A) A schematic diagram of generation of F2 TMEM41B-deficient mice. (B and C) There was no significant morphological difference between F2 generation TMEM41B+/− mice and WT (C57BL/6N) mice. (D) Genotyping of F2 generation TMEM41B+/− mice using genomic DNA from tail clips. (E) Sanger sequencing of PCR products from F2 generation TMEM41B+/−mice. (F) The relative TMEM41B gene expression level of F2 generation TMEM41B+/− mice liver tissue was reduced by about 70% compared with WT mice liver tissue. (G) Western blot assays analysis the autophagy maker p62 protein of liver and kidney tissue from WT and TMEM41B+/− mice with starvation treatment. (H) The serum lipid concentrations of WT and TMEM41B+/− mice (before MHV infection) were measured by corresponding reagent kit: TG (Rayto, S03027); CHO (Rayto, S03042); HDL (Rayto, S03025); LDL (Rayto, S03029). F, forward primer; R, reverse primer; WT, wild-type; NC, negative control; del, deletion, E1-7, exons from 1 to 7; bp, base pairs; M, DNA marker; sgRNA, small guide RNA; F0, founder generation mice; F1, F1 generation mice; F2, F2 generation mice; TG, triglyceride; CHO, cholesterol; HDL, High-density lipoprotein; LDL, Low-density lipoprotein. *P < 0.05; **P < 0.01; ***P < 0.001; ns, no significant. P values were determined by two-sided Student’s t-test. Data are representative of at least three independent experiments.

    (TIF)

    S1 Data. Sequencing results of sgRNAs (PigGeCKO) in each of three rounds of TGEV screening after challenge.

    (XLSX)

    S2 Data. Sequencing results of sgRNAs (Focused-CRISPR library) in the third and fifth rounds of TGEV screening after challenge.

    (XLS)

    S3 Data. Differential gene expression analysis derived from RNA-seq.

    (XLSX)

    S4 Data. Primer pairs and sgRNA targeting sequences used in this study.

    (XLSX)

    Attachment

    Submitted filename: Response to reviewers.docx

    Attachment

    Submitted filename: response to reviewers .docx

    Data Availability Statement

    Raw sequencing data and processed counts data for sgRNA libraries that support the findings of this study have been deposited in National Center for Biotechnology Information’s Gene Expression Omnibus and are accessible through GEO Series accession number: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE169113.


    Articles from PLoS Pathogens are provided here courtesy of PLOS

    RESOURCES